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The emergence of antibiotic-resistant bacterial pathogens and the discovery of
new bacterial pathogens have motivated the development of novel antibacterials. One
recently proposed strategy is to target pathogenic bacteria specifically by inhibiting
virulence mechanisms as opposed to killing bacteria indiscriminately, which includes
commensal strains. Due to the increased appreciation for the role commensal bacteria
play in the immune response and the importance for maintaining a healthy microbiota,
specifically targeting pathogenic bacteria is a desirable goal to attain. Genetic and
biochemical studies have highlighted type III secretion systems (T3SSs) as essential
components for infection of host cells by Gram-negative bacterial pathogens. Small
molecules that target type III protein secretion may therefore represent a new class of
antibacterial agents and provide a platform for evaluating an anti-virulence approach.
The salicylidene acylhydrazides (SAHs) are a class of compounds that prevent
secretion of bacterial effector proteins through the T3SS and attenuate infection from
various species of Gram-negative pathogens; however, the molecular target(s) of these
compounds remains unknown, and the potency of these compounds is not optimal. To
discover the molecular target(s) of the SAHs in Salmonella typhimurium and determine
their mechanism of action, I synthesized several alkynyl SAH analogs and employed
bioorthogonal

labeling

techniques

for

proteomic

analysis

of

their

protein-binding partners. Through structure-activity relationship (SAR) analysis of the
alkynyl analogs, I discovered important features for the inhibitory activity of the SAHs
and observed that they covalently modify many S. typhimurium proteins; however, the
protein targets responsible for the inhibitory activity of SAHs remains to be determined.
Repurposing chemical inhibitors to target host enzymes required for infection has
emerged as an alternative approach to subvert rapid antibiotic resistance in bacterial
pathogens. Towards this goal, the isoquinolinesulfonamide H-89 was reported to limit
Salmonella replication in macrophages through inhibition of Akt, a host kinase that is
activated during infection. However, more potent Akt-specific inhibitors are less effective
at inhibiting bacterial replication, suggesting an alternative mechanism of action for H89. I discovered that H-89 does not target Akt in host cells to restrict bacterial replication,
but more likely prevents bacterial replication by inhibiting the expression of S.
typhimurium T3SS components and effector proteins required for bacterial invasion and
replication in host cells. As H-89 does not interfere with bacterial growth in liquid
culture, these results highlight isoquinolinesulfonamides as a new class of lead
compounds for targeting bacterial virulence.
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CHAPTER 1 – Introduction

1.1 Targeting virulence as an alternative strategy to antibiotics
The emergence of multidrug-resistant bacterial strains and new microbial
pathogens necessitates that novel antimicrobial strategies are developed to replenish our
waning antibiotic arsenal [1,2]. The rate at which bacteria acquire resistance to antibiotics
is faster than we are developing new ones. The widespread use of antibiotics over the
years has applied selective pressure that gives a competitive advantage to bacteria
containing resistance mechanisms [3]. Despite the increase in antibiotic-resistant strains,
unfortunately there has been a decrease in the number of new drugs to combat them (Fig.
1.1). Over the last 40 years, there has been a major lull in the deployment of new
antibiotics, and antibiotic resistance has quickly developed. A new approach to
antibacterials is necessary if we hope to keep up with the ever-evolving bacteria. The
discovery of antibiotics has been one of the most impactful events to benefit human
health [4], but currently we are regressing towards the pre-antibiotic era.
Not all bacteria are harmful; however, as an increasing number of studies have
been begun to reveal specific beneficial mechanisms of commensal bacteria on host
immunity [5-9]. Thousands of bacterial species make up the microbiota that inhabit the
gastrointestinal tract of humans [7]. These bacteria establish colonization resistance to
infection by pathogenic bacteria and are crucial for the proper development of the
immune system [6]. They stimulate intestinal epithelial cells to secrete antimicrobial
peptides [7], affect the number and activity of dendritic cells [10], and even single
1

bacterial species are capable of restoring the balance of T helper cells in germ-free mice
[11,12].
Antibiotic disruption of bacterial communities can alter host immunity and
exacerbate microbial infections [13]. Most antibiotics indiscriminately kill bacteria,
including beneficial commensals. Since they play a large role in homeostasis of the
immune system, antibiotic treatment depletes many of the beneficial effects commensals
bestow onto their hosts. Treatment with antibiotics completely changes the composition
of the normal microbiota, and these effects are long-lasting [13,14]. This not only paves
the way for opportunistic pathogens to establish infection [15] but also renders the host
more susceptible to other enteric infections [16,17].
Therapeutic strategies that target bacterial virulence rather than growth have thus
received considerable attention [1,2], as these approaches are proposed to selectively
disarm pathogens while preserving the integrity of the host microbiome. It is also
hypothesized that anti-virulence compounds could apply less selective pressure to
develop resistance mechanisms, but as of now it is unsubstantiated.

2

Antibiotic deployment

Antibiotic resistance observed

Figure 1.1 Antibiotic deployment and resistance. Taken from [2], this timeline shows
the relationship between when an antibiotic was first deployed (top) and when resistance
to that antibiotic was first observed (bottom).

1.2 Bacterial virulence mechanisms can be targeted with small molecule inhibitors
The discovery of many bacterial virulence mechanisms including virulence gene
regulation, adhesins, protein secretion systems, and associated toxins are new targets for
anti-virulence strategies [1,2] (Fig. 1.2). At the start of infection, bacteria sense their
environment and up-regulate the expression of virulence genes, which primes the bacteria
for establishing infection. This leads to the production of toxins and effector proteins that
disrupt host cell functions and cause disease. Bacteria then use specialized secretion
systems to deliver these toxins and effectors into the host cells to which they have
adhered. Disrupting any one of these aspects of pathogenesis can lead to attenuated
infection.

3

Figure 1.2 Bacterial virulence mechanisms to target. Taken from [2], bacterial
virulence mechanisms can be targeted with small molecule inhibitors. Inhibition of
virulence gene regulation, bacterial adhesion to host cells, delivery of toxins, or toxin
function could lead to decreased infection.

Bacteria themselves are not inherently harmful; the toxins they produce are what
cause disease. Inhibiting toxin activity is therefore a direct method for inhibiting
virulence. This is the principle behind antitoxin development. This approach can be
achieved by inhibiting toxin activity directly or altering the host response [18]. One
difficulty with this approach is that many bacterial effectors exert their function by
mimicking host factors; blocking this interaction could also block the endogenous
4

activity of host proteins [19]. Anthrax lethal factor can be inhibited by a small molecule
(Fig. 1.3A) that binds its active site or by adding soluble Anthrax receptors that compete
for binding [20,21].
Many bacterial species sense their environment and communicate to each other on
a population level through a process called “quorum sensing” [22]. It is a method for
bacteria to communicate between species and also to evaluate its own population density.
The external environment and population density regulate virulence gene expression.
When pathogens sense they are in an appropriate situation to cause infection, they can
up-regulate expression of virulence genes. Many Gram-negative pathogens use acylhomoserine lactones (AHLs) as the signaling molecules that mediate quorum sensing
[22,23]. Though many species share a similar pathway, the receptors can be selective for
their specific signaling molecule [22]. Halogenated furanones (Fig. 1.3B) are analogs that
have been used in vitro to inhibit the signaling process stimulated by AHLs [24], and in a
mouse model of P. aeruginosa infection, they were shown to inhibit quorum sensing and
increase survival from a lethal dose of bacteria [25], validating the potential of this
approach.
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Figure 1.3 Structures of anti-virulence compounds. A) Structure of compound that
inhibits Anthrax lethal factor. B) Halogenated furanones disrupt quorum sensing. C)
LED209 inhibits QseC two-component signaling. D) Bicyclic 2-pyridones inhibit pilus
assembly, preventing adhesion.

Bacteria also utilize two-component signaling pathways to sense their
environment and respond accordingly [22]. Targeting two-component sensory systems
led to the discovery of a compound that inhibits QseC-dependent virulence gene
activation in enterohemorrhagic Escherichia coli [26]. QseC is a histidine kinase sensor
that is conserved amongst several pathogens and regulates transcription of virulence
genes. The compound LED209 (Fig. 1.3C) prevents transcription of virulence genes and
secretion of effectors without inhibiting bacterial growth. It also increased the lifespan of
mice infected with S. typhimurium and F. tularensis [26].
For bacteria to establish infection, they first attach to host cells. They do so with
adhesins that recognize cell surface receptors on the host cells [27]. Small molecule
inhibitors could be developed to prevent either the formation of the adhesins or the
binding to host cell receptors. The bicyclic 2-pyridones are a class of compounds that
prevents the formation of the adhesins that recognize and bind to host cells [28,29] (Fig.

6

1.3D). They were shown to prevent adhesion of E. coli in an ex vivo model of infection
[28].

1.3 Type III secretion systems (T3SSs) are essential to infection
After bacteria adhere to host cells, they use specialized secretion systems to
deliver the toxins and effector proteins into the host cell. One example is the type III
secretion system (T3SS), which is a molecular syringe that is common to many Gramnegative pathogens including Chlamydia, E. coli, Pseudomonas, Salmonella, Shigella,
and Yersinia [30]. These pathogens use the T3SS to inject effector proteins from the
bacteria into the host cytosol. Amongst the many bacterial virulence mechanisms that
have been discovered, protein secretion systems appear to be prime targets for small
molecule inhibition of infection [31-33].
The highly conserved T3SS is central to the virulence of many human Gramnegative pathogens [30,34,35]. Mutants defective in T3SS activity are attenuated in their
ability to cause infection [36]. These two aspects make targeting T3SSs an attractive
strategy; inhibitors can have a marked effect on infection with the potential for broadspectrum activity. The T3SS is a transmembrane machine comprised of about 20 proteins
that assemble into a needle-like complex (Fig. 1.4A) that spans the bacterial membranes
and functions in a highly regulated manner to transport effector proteins from the
bacterial cytoplasm directly into host cells (Fig. 1.4B) [37-40]. Construction of T3SSs
requires both structural components and ancillary proteins for the assembly process
[41,42]. The basal body spans the inner (IM) and outer (OM) membranes of the bacteria
[41,42]. The rings that span the IM are brought to the envelope by a Sec-dependent
7

pathway and anchored by N-terminal lipidation [34]. A short rod connects the IM rings to
the OM components, which belong to the secretin family of pore-forming proteins [42].
The needle, which varies in length between species and strains, is a polymer of helical
proteins that protrudes from the bacterial surface and delivers protein effectors outside
the bacteria [41,42]. The tip of the needle is composed of a complex known as the
“translocon,” which can insert itself into the host cell membranes [30,41]. The T3SS is
activated by environmental cues, and upon contact with host cells, secretes and
translocates protein effectors into the host cytoplasm (Fig. 1.4B) [30]. T3SSs thus
facilitate highly coordinated and regulated secretion of specific bacterial protein effectors
during infection [43].

!
Figure 1.4 T3SS needle apparatus. A) Electron micrograph and models of T3SS needle
apparatus. B) Diagram for translocation of effector proteins into host cells. Figures taken
from [30].
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Hundreds of effector proteins among diverse bacterial pathogens have been
identified as potential substrates of T3SSs, with as many as 30 different effector proteins
being secreted from a single pathogen [35]. Several bacterial effectors can directly induce
host cell death to facilitate bacterial pathogenesis [44,45]. Other bacterial effectors mimic
host signaling proteins and enzymes to alter cellular signaling pathways. This allows
bacteria to enter and replicate within the host cells while evading detection and
destruction by the host immune system [46]. Depending on the bacterial pathogen, T3SSs
can thus facilitate bacterial entry and replication in host cells or cause host cell death
directly. Even though many detailed molecular mechanisms regarding the biogenesis of
T3SSs and bacterial effector functions are still under investigation, genetic and
biochemical studies of many Gram-negative bacterial pathogens have revealed that
effector translocation by T3SSs is crucial for infection [42]. Despite normal in vitro
growth rates, T3SS bacterial mutants can not deliver protein effectors into host cells,
which renders the pathogens avirulent and significantly attenuated in their ability to cause
disease in animals [42]. Moreover, directly blocking the injection of protein effectors into
host cells through active or passive immunization using specific antibodies further
supports T3SSs as key virulence mechanisms for infection.
T3SSs have emerged as attractive targets for small molecule anti-virulence
therapeutics and have motivated several high-throughput screens (HTSs) in search for
specific chemical inhibitors that block the secretion and translocation of bacterial effector
proteins [31-33]. As T3SSs have not been reconstituted in vitro, the search for small
molecule inhibitors has largely employed cell-based assays for protein secretion coupled
to sensitive and high-throughput readouts (Fig. 1.5) or targeted screens against the
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enzymatic activity of the ATPase required for protein secretion. Several classes of small
molecules have now been identified from these screens (Tables 1.1, 1.2, and 1.3), which
are summarized below with their potential mechanisms of action and prospects for
clinical development [47].
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Figure 1.5. Assays for bacterial effector secretion and HTSs. A) Whole cell HTS
using a Yersinia pseudotuberculosis (yopE:luxAB) strain [48] that utilizes a
transcriptional readout linked to secretion. B) Whole-cell HTSs were performed using an
effector-enzyme fusion where the enzymatic activity can be monitored by fluorescence
[49,50]. C) A bacterial effector is fused with β-lactamase (βla) that cleaves a βlasensitive FRET probe, CCF2-AM, in the host cells [51]. D) GFP-labeled chaperones were
used as probes to visualize translocation of bacterial effectors by imaging effector
accumulation in the cytosol of the host cells [52]. E) Upon T3SS effector translocation,
the association of the two fragments, the small 13-amino-acid 11th strand of the GFP βbarrel and the complementary fragment of the first 10 GFP strands, leads to GFP
fluorescent-tagging of the effector population in the host cells [53]. F) The fluoresceinbased biarsenical dye FlAsH in the host cells allows the labeling of effectors with a
genetically encoded sequence containing the tetracysteine repeat motif as the tag [54-56].
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Figure 1.5
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1.4 Inhibitors of T3SSs in Gram-negative pathogens

1.4.1 Salicylidene acylhydrazides
The salicylidene acylhydrazides (SAHs) were the first class of small molecules
identified from a T3SS effector screen [48]. Kauppi et al. developed a whole cell HTS
using a Yersinia pseudotuberculosis reporter strain that utilizes a transcriptional readout
linked to secretion (Fig. 1.5A) [48]. They engineered the luciferase luxAB gene under the
control of the effector yopE promoter. When grown at 37 °C in Ca2+-rich media, LcrQ
prevents T3SS gene expression. Upon contact with a eukaryotic cell or depletion of Ca2+,
LcrQ is secreted via the T3SS, thus releasing transcriptional repression of type III
secretion genes such as yopE [57]. Under these conditions, this strain will then express
luciferase and luminescence can be used to monitor yopE expression. Using this assay,
Kauppi et al. screened 9,400 compounds for their ability to block expression of luciferase
activity. Luminescence was measured after bacteria were incubated with compound in
Ca2+-depleted media. In wells with inactive compounds, LcrQ would be secreted and
luciferase would be expressed. For compounds that block T3S, LcrQ would remain in the
cell and repress expression of the luciferase gene. Since this assay monitors loss of signal
on a transcriptional level, follow-up assays are required to assess the activity of
compounds on type III secretion directly. Compounds that affect the growth of the
bacteria are excluded, and compounds with effects on transcription would also result in
hits by indirectly affecting type III secretion.
Three notable classes of compounds were discovered to prevent type III secretion
at low micromolar concentrations without affecting growth of the bacteria: the
13

sulfonylamino-benzanilides, salicylanilides, and salicylidene acylhydrazides. Incubation
of bacteria with each class resulted in decreased levels of secreted effectors into culture
supernatant, confirming the transcriptional readout. The individual compounds have
varying effects on transcription and motility, which suggests they have different targets
and mechanisms of action. The flagellar system is related to the type III secretion
machinery, so compounds that affect one could also target the other. The sulfonylaminobenzanilides did not affect motility or general transcriptional regulation of the T3SS, but
only one follow-up study has been done, potentially due to their limited solubility [58].
The salicylanilides have no effect on motility and likely work upstream of a
transcriptional activator of the Yops, potentially by affecting two-component signaling,
thus indirectly affecting type III secretion. There are other reports confirming their effect
on transcription [59,60]. The salicylidene acylhydrazides, specifically INP-0007 from this
study, affected both secretion and motility without generally affecting transcription
(Table 1.1, entry 1). This suggests a conserved component between the two systems as a
potential target. Inhibiting secretion and motility is advantageous for an anti-virulence
compound, making this class a good candidate for follow-up studies.
Since the initial discovery of the salicylidene acylhydrazides displaying T3SS
inhibitory activity in Yersina, follow-up studies in Yersinia demonstrated INP-0007
blocks secretion in a constitutively secreting mutant and prevents bacterial invasion of
HeLa cells [61]. Compounds in this class have since been shown to have T3SS inhibitory
activity in several Gram-negative pathogens including E. coli [62,63], Chlamydia [6469], Salmonella [50,70-72], and Shigella [73], which results in an attenuation of
infection. Various INP-0007 derivatives were shown to prevent invasion of Yersinia,
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Salmonella, and Shigella, disrupt the infectious cycle in Chlamydia, and decrease the
number of attachment and effacement lesions in a bovine epithelial cell line when
infected with E. coli [62]. INP-0007 and INP-0403 were shown to inhibit T3SS-induced
hemolysis in erythrocytes and decrease the secretory and inflammatory responses in vivo
with a bovine intestinal ligated loop model when infected with Salmonella (Table 1.1,
entries 1 and 5), but the caveat for drug development is that these protective effects were
only observed when the bacteria were pre-treated with inhibitor [70]. In Chlamydia,
however, even when inhibitor was added 24 hours post-infection to HeLa cells, it still had
a significant impact on bacterial replication [68]. This led to some pre-clinical studies and
in vivo experiments with Chlamydia-infected mice [74]. Gylfe et al. used mice injected
with compound to analyze the pharmacokinetics of two of the most potent inhibitors of
Chlamydia replication. The most potent compound displayed poor pharmacokinetic
parameters, so they applied it topically to mice inoculated intravaginally with C.
trachomatis. They saw a significant decrease in the number of inclusion forming units
(IFUs) for compound-treated mice over the 4 weeks monitored. Moreover, they did not
observe any noticeable effect on strains of lactobacilli: commensals that are essential for
maintaining the balance of the vaginal microflora. These results demonstrate the utility of
the SAHs to be used in vivo to treat Chlamydia infection.
More recently, the SAHs have been shown to have antiviral effects as well [75].
Forthal et al. screened 25 SAHs for anti-HIV-1 activity and focused on 4 that had IC50
values in an infection assay in the single-digit micromolar range and were not cytotoxic
to cells. They were effective against several strains of HIV-1 and were active in a vaginal
and semen simulant, demonstrating their potential as a topical applicant for inhibiting the
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transmission of sexually transmitted diseases.
While there is variability in the exact structure of active SAHs between species,
there is a common core scaffold. One study used statistical molecular design (SMD) and
quantitative structure-activity relationships (QSAR) on 50 compounds tested in Yersinia
to make predictions about untested compounds [76]. Of eight candidate compounds, they
were able to correctly predict that three would be inactive, but only three of the five
predicted to be active demonstrated inhibitory activity. Though there was no obvious
consensus motif that confers activity, the authors found that the pKa of the phenol was
the most important property in the model and that the electrostatic potential of the carbon
atoms in that aromatic ring may play a key role.
Though there have been several studies using the salicylidene acylhydrazides in
various bacterial species, the precise target(s) and mechanisms of action remain unclear.
Since these compounds have broad-spectrum inhibitory activity, it is likely that they
target something conserved among the species. It was initially proposed that the
compounds act directly on the T3SS machinery, and one report in Shigella suggests that
incubation with INP-0400 affected needle assembly [73] (Table 1.1, entry 4). Further
support for this notion is that the T3SS needle complex is related to the flagellar
assembly, and motility is affected in Yersinia [48] and Salmonella [71]. Several reports
have examined the effects these compounds have on transcription. In Chlamydia, Wolf
and co-workers found that INP-0007 down-regulates some virulence genes, and while
levels of needle components are unaffected, effectors accumulate intracellularly [66].
Another study performed RT-PCR of virulence genes during infection of HeLa cells
where compound was added at the time of infection [68]. They also observed that only
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some virulence genes are down-regulated when incubated with active compound, and
importantly, they used an inactive compound as a negative control and saw no differences
between that and the DMSO sample. In E. coli, four compounds with varying potency all
down-regulated genes in the locus for enterocyte effacement, but there was large
variation between strains [62]. When the transcriptome in Salmonella incubated with
various inhibitors was examined, the needle complex ATPase InvC and the HilD
regulator were down-regulated, but no major effects on HilA or the effectors themselves
were observed [72]. Taken together, it is clear the salicylidene acylhydrazides have some
transcriptional effects; however, it is not obvious if this is a direct effect and the cause of
secretion inhibition or the result of a feedback loop.
In Chlamydia [68] and Salmonella [72], it has been reported that adding
exogenous iron to the cultures can prevent the inhibitory effects of the SAHs
acylhydrazides, suggesting iron restriction as a potential mechanism of action. Iron
transport and acquisition genes are up-regulated in Salmonella upon treatment with
several inhibitors, however, neither the up-regulation of iron-related genes nor an effect
from adding exogenous iron is observed in Yersinia. Also, an inactive compound was
shown to bind iron to the same extent as an active compound [68], thus casting doubt on
an iron-restriction mechanism.
Roe and co-workers attempted to identify the targets of the salicylidene
acylhydrazides using a biochemical approach [63]. They synthesized two analogs of
ME0052 (Table 1.1, entry 2) and ME0055 (Table 1.1, entry 3) for affinity purification of
binding partners from E. coli lysate. After trypsinization and LC-MS/MS analysis, 16
proteins were identified, and three were suggested binding partners by Far Western

17

analysis using a biotinylated version of a much less active compound: Tpx (thiol
peroxidase), WrbA (NAD(P)H quinine oxidoreducase), and FolX (dihydroneopterin-triP-epimerase). Knockouts of each gene results in down-regulation of flagellar components
and up-regulation of T3SS genes, the opposite of what is observed with compound
treatment. Deletion mutants of Tpx and WrbA secrete more effectors, and they are as
virulent in infecting macrophages, but adding ME0052 can still inhibit both processes.
The authors thus suggest the inhibition of T3SS activity is due to a polypharmacological
effect on proteins involved in metabolism, which then results in a dis-regulation of
bacterial virulence. Given the diverse pharmacological effects of salicylidene
acylhydrazides that have been reported, the precise mechanism of action for these
compounds remains unclear.
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Table 1.1 Compound structures of salicylidene acylhydrazides and assays tested.
Compound

Regulation
C trachomatis:
Down-regulates
transcription of
late-cycle
virulence genes

1
Br
HO

O
N
H

N

Secretion/Translocation
C. trachomatis: Prevents
IncA secretion during
infection

T3SS
IC50
~15 µM
~5 µM

S. typhimurium
Y. pseudo-tuberculosis

Br

O2N

Y. pseudo-tuberculosis:
Prevents YopH
translocation into HeLa

INP-0007, D8

2

Br
HO

O
N
H

N

Br

N

INP-0010, D9, ME0052

3
HO

O

OH

N

N
H
O2N

INP-0031, ME0055

4
HO

O
N
H

EHEC: Downregulates
transcription of
LEE but not
iron-related
genes
C. pneumoniae,
S. typhimurium:
Down-regulates
transcription of
some virulence
genes

EHEC: Inhibits Tir and
EspD secretion

EHEC: Downregulates
transcription of
LEE but not
iron-related
genes and upregulates
flagellum
expression

EHEC: Inhibits Tir and
EspD secretion

S. flexneri:
Affects needle
complex
assembly

S. typhimurium

Cl

S. typhimurium:
Down-regulates
transcription of
invC and hilD
but not hilA or
effectors

S. typhimurium

N
H

N

INP-0403, D4

Cl

48,
50,
61,
66,
70,

~25 µM

EHEC: Reduces number
of A/E lesions on
bovine epithelial cells

62

C trachomatis: Inhibits
replication in HeLa and
McCoy cells
S. typhimurium:
Reduces HeLa
cytotoxicity
S. flexneri: Reduces
invasion of HeLa and
macrophage
cytotoxicity

65,
68,
71,
73

S. typhimurium

S. flexneri

~25 µM
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Y. pseudotuberculosis:
Inhibits motility

62,
67,
71,

INP-0400, D1

HO

Ref

C trachomatis: Inhibits
replication in
mammalian cell lines
S. typhimurium: Inhibits
invasion of MDCK cells
and replication in
macrophages
Y. pseudo-tuberculosis:
Reduces macrophage
cytotoxicity

Cl

O

C. trachomatis: Inhibits
replication in HeLa
S. typhimurium:
Reduces hemolysis of
erythrocytes, invasion
of HeLa, and immune
response in bovine
ligated loop model
Y. pseudo-tuberculosis:
Inhibits invasion of
HeLa

Other Pathways

~25 µM

N

5

Infection

S. typhimurium:
Reduces hemolysis of
erythrocytes, invasion
of HeLa, and immune
response in bovine
ligated loop model

S. typhimurium:
Effects reversed
with exogenous
iron

70,
71,
72,

1.4.2 2-Imino-5-arylidene Thiazolidinones
A

whole-cell

HTS

in

Salmonella

identified

the

2-imino-5-arylidene

thiazolidinones as broad inhibitors of T3S [49]. The screen was performed by
engineering a Salmonella strain where the secreted effector SipA was fused to a portion
of a Yersinia protein YplA, that contained phospholipase A2 activity (Fig. 1.5B). The
phospholipase A2 activity could then be measured with a fluorogenic substrate. Using
this strain, they screened 92,000 small molecules from natural and synthetic libraries.
After ruling out compounds that affected growth or were unsuitable for drug
development, they followed up on 25 compounds. Excluding compounds that had an
effect on general transcription, translation, or Sec-dependent secretion left seven
molecules for follow-up studies. Six of these were found to affect T3SS gene expression,
leaving one that might specifically target the T3S process or assembly directly.
The one compound Felise et al. pursued was a 2-imino-5-arylidene thiazolidinone
(TTS29) (Table 1.2, entry 1), and it was shown to have T3SS inhibitory effects in
Yersinia, Pseudomonas aeruginosa, and Francisella novicida, demonstrating broadspectrum inhibitory activity. By purifying the needle complexes of Salmonella, they
found that compound-treated samples had lower levels of needle components, but wholecell and membrane fraction levels were unchanged, suggesting that the compound
disrupts needle complex assembly. No effect was observed on motility or the levels of
flagellar components, suggesting the effect was specific to the T3SS. They also
discovered that TTS29 affects type II secretion (T2S) and the related type IV pili
assembly. After examining what is common to all of the affected systems and not present
in the flagellar system, it was proposed that TTS29 acts by disrupting secretin
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interactions, thus affecting needle complex assembly or stability but not the flagellar
system. These effects on the T3SS carried over into an infection setting, as the compound
was able to prevent Salmonella-induced lysis of macrophages and the hypersensitivity
response in tobacco plants from the plant pathogen Pseudomonas syringae.
One major drawback is the low potency of TTS29, as several hundred micromolar
is required to have an inhibitory effect. Subsequent SAR analysis demonstrated the
importance of the imino nitrogen, its aryl group, and the substitution pattern on the
arylidene ring while the amido nitrogen tolerated modification. A TTS29-analog in this
study displayed higher potency in every assay tested without affecting bacterial growth
(Table 1.2, entry 2). This led to further modification of the amido nitrogen, with several
analogs containing a dipeptide chain displaying low micromolar IC50 values for inhibition
of SipA [77]. Tethered thiazolidinone dimers (Table 1.2, entry 3), some of which are
linked with a peptide, displayed similar potencies [78]; however, no follow-up studies
have been reported with these compounds.
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Table 1.2 Compound structures of 2-imino-5-arylidene thiazolidinones and assays tested.
IC50 values are reported based on the inhibition of SipA secretion as determined by
Western blot.
Compound

Regulation

1
N
N

S

MeO

O
HO

Secretion/Translocation

T3SS
IC50

Infection

Other Pathways

83 µM

P. syringae:
Prevents HR
response in
tobacco leaves
S. typhimurium:
Reduces
macrophage
cytotoxicity

S. typhimurium: No
effect on flagellar
system or motility
P. aeruginosa:
Inhibits T4dependent motility &
T2S

49,
77,
78

S. typhimurium:
Reduces
macrophage
cytotoxicity

P. aeruginosa:
Inhibits T2S

49,
77,
78

S. typhimurium:
Inhibits needle
complex
assembly, No
effect on general
transcription

S. typhimurium

S. typhimurium:
No effect on
general
transcription

S. typhimurium

3 µM

S. typhimurium: Inhibits
secretion of SipA

5 µM

Y. enterocolitica
F. tularensis

TTS29

MeO

2
N
S

MeO

H
N

N

NH2

O

O
HO

O

Ref

HN

MeO

NH

H2N

TTS29-analog

3

MeO
OH

N

78

S
OMe

N
O

HN
N

O

N

O
S

MeO
HO

OMe

1.4.3 Other chemotypes from HTSs
A few other HTSs have revealed several other classes of T3SS inhibitors. Janssen
Pharmaceuticals employed an assay which measures levels of the secreted effector
protein ExoU from P. aeruginosa and SipA and SopE from S. typhimurium as the
readouts of T3SS inhibition [79]. The majority of the inhibitors that exhibited low
micromolar potencies were comprised of a common N-acyl p-Cl phenylalanine moiety
(Table 1.3, entry 1). However, this class of compounds lacks the broad-spectrum anti-
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T3SS activity across different Gram-negative pathogens, and no further development has
yet been reported.
Microbiotix Pharmaceuticals has identified five inhibitors from a library of
80,000 compounds through two distinct functional bioassays [80]. First, compounds were
screened against a transcriptional fusion of the Photorhabdus luminescens luxCDABE
operon to the P. aeruginosa exoT effector gene. The compounds were then selected based
on the inhibition of the secretion of a P. aeruginosa ExoS effector-β-lactamase fusion
protein (Fig. 1.5C) and also of native ExoS by the SDS-PAGE analysis of culture
supernatants. To demonstrate the broad-spectrum efficacy of the compounds, they were
found to also antagonize Yersinia T3S and one compound, MBX1641, also targeted
Chlamydia T3S (Table 1.3, entry 2). Interestingly, contrary to typical HTS hits,
Microbiotix compounds contained chiral centers and through a series of synthetic efforts,
it was shown that the R enantiomer was the preferred stereochemistry. With a stringent
structure activity relationship, these compounds might see many obstacles moving
forward; however, other scaffolds identified in the screen could be explored in the future.
Harmon et al. devised a HTS to identify compounds that inhibit the T3Sdependent translocation of Yersinia effector proteins, Yops, into host cells [51]. This
translocation-monitoring FRET-based system employed a chimeric protein, E-TEM,
which encodes the first 100 amino acids of YopE, containing the secretion and
translocation signals, fused to a fragment of β-lactamase (TEM) (Fig. 1.5C). The
substrate, CCF2-AM, consists of two fluorophores conjugated by a lactam ring.
Normally, the substrate fluoresces green due to FRET between the fluorophores. TEM
can cleave the lactam ring between the fluorophores, leading to the loss of FRET and
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resulting in blue fluorescence. If Y. pseudotuberculosis translocates E-TEM into host
cells, the substrate will be cleaved and the cells will fluoresce blue. The green-to-blue
ratio was measured to determine whether the compounds could block the translocation of
E-TEM. Notably, they have identified six compounds that specifically inhibit
translocation of Yops into mammalian cells but not Yop synthesis or secretion (Table
1.3, entry 3). These six diverse compounds lacked a consensus pharmacophore, yet they
inhibited translocation of effectors into the host cell while not affecting the synthesis of
T3SS components or effectors, assembly of the T3SS, or secretion of effectors.
Interestingly, C20 reduced adherence of Y. pseudotuberculosis to target cells.
Additionally, the compounds were shown to cause leakage of Yops into the supernatant
during infection and reduced polarized translocation. Furthermore, several molecules also
inhibited P. aeruginosa ExoS-mediated cell rounding, suggesting that the compounds
target factors that are conserved between these two pathogens.
Similar to the reported yopE:luxAB strain [48], Pan et al. screened a collection of
70,966 compounds using a Y. pestis luciferase reporter strain [81]. Four new compounds
were identified to inhibit secretion of Y. pestis T3SS effector proteins YopD, YopH, and
YopM at micromolar concentrations without affecting bacterial growth. Moreover, two of
the four compounds (Compounds 1 and 2, Table 1.3, entry 4) also attenuated T3SSmediated secretion of EPEC effector proteins. In all, compounds discovered from this
library are likely to have different mechanisms of action and targets from each other.
Li and co-workers adopted a cell-based assay that measures the T3S-dependent
secretion of a chimeric SopE-β-lactamase fusion and identified a class of triazine-based
compounds (Table 1.3, entry 5) as inhibitors of T3S [82]. Active compounds can
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selectively reduce the level of SipB in the supernatant fraction of Salmonella culture
without affecting the production of SipB intracellularly. Moreover, these compounds also
diminished the level of ExoU in the supernatant of P. aeruginosa cultures. No further
development has been reported since the patent.
In an effort to identify compounds that protect Chinese hampster ovary (CHO)
cells against the T3S-depedent cytotoxic effects of the P. aeruginosa effector ExoU, Lee
et al. reported pseudolipasin A as a specific inhibitor for the phospholipase A2 activity of
ExoU with an IC50 of 7 µM (Table 1.3, entry 6) [83]. They found that pseudolipasin A
did not prevent the type III secretion of ExoU or its transolocation into CHO cells but
inhibited the phospholipase A2 activity of ExoU directly and specifically. A collection of
structural analogs was used to demonstrate a conserved pharmacophore for phospholipase
A2 inhibitory activity.
Starting with an in silico screen, a number of N-hydroxybenzimidazole-based
scaffolds was synthesized to block the binding of the Yersinia transcription factor LcrF to
DNA (Table 1.3, entry 7) [84]. LcrF regulates the expression of the Yersinia T3SS. With
more detailed SAR studies, a number of novel compounds potently inhibited the
secretion of Yops. They also demonstrated that these compounds were capable of
protecting macrophages from Y. pseudotuberculosis-induced cytotoxicity, decreasing the
bacterial burden in a mouse infection model, and increasing survival from a lethal dose of
bacteria [85].
Swientnicki et al. has recently reported in silico studies to identify inhibitors to
target the Yersinia pestis T3SS ATPase YscN (Table 1.3, entry 8) [86]. The authors
validated YscN as a therapeutic target by deleting the catalytic domain of the yscN gene
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in Y. pestis CO92 and showed a reduction of over three million-fold of bubonic plague in
the Swiss-Webster mouse model. The validated but diverse inhibitors had IC50 values
below 20 µM in an in vitro ATPase assay and were also found to inhibit the homologous
BsaS protein from the Burkholderia mallei animal-like T3SS at similar potency.
Moreover, these compounds inhibited YopE secretion and attenuated Y. pestis toxicity in
mammalian cells. These data demonstrate the possibilities of targeting and inhibiting
ATPases of T3SSs in other pathogens.

1.4.4 Natural Products
In addition to synthetic chemical libraries, natural product extracts have been
surveyed for compounds with T3SS inhibitory activity. Bioassay-guided fractionation of
the extracts from the marine sponge Caminus sphaeroconia led to the isolation of a series
of lipidated pentasaccharides that possess potent anti-T3SS activity (Table 1.3, entry 9)
[87,88]. Analysis of EPEC culture supernatants showed that caminoside A selectively
diminished the level of a T3S-dependent effector protein EspB while not affecting the
level of EspC, a type V-dependent effector. The potency of caminoside A is
approximately 20 µM without affecting the growth of the pathogens [87], yet further
development of the caminosides has not been reported. Alternatively, guadinomines
isolated from Streptomyces sp. K-01-0509 were reported to inhibit EPEC T3S-dependent
lysis of sheep blood erythrocytes with an IC50 value of 20 nM in a whole cell assay
(Table 1.3, entry 10) [89,90]. Even though this class of natural products might be the
most potent inhibitors to date, major synthetic efforts are needed to produce pure material
for further studies [91].
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From a screen of monitoring T3SS-mediated hemolysis from enteropathogenic E.
coli (EPEC), Abe and co-workers identified aurodox, a linear polyketide from
Streptomyces, as a specific T3SS inhibitor [92]. Aurodox potently inhibited T3SSmediated hemolysis with an IC50 value of 1.5 µg/ml without affecting bacterial growth
(Table 1.3, entry 11). By Coomassie blue staining and Western analysis of the
supernatant fraction, aurodox specifically diminished the levels of effector proteins such
as EspB, EspF, and Map without affecting the expression of the housekeeping protein
GroEL. Moreover, aurodox allowed mice to survive a lethal dose of Citrobactor
rodentium, a model bacterium for human pathogens such as EPEC. Beyond the
antibacterial drug development, the discovery of aurodox highlights the possibility that
microbes may produce small molecules that can antagonize T3SSs in chemical ecology.
Without the use of a HTS, Li et al. discovered that cytosporone B (Table 1.3,
entry 12) and its analogs can effectively prevent the secretion of SPI-1 effectors without
affecting growth or the levels of the flagellar proteins in Salmonella typhimurium [93].
Cytosporone B is a reported agonist for the nuclear orphan receptor Nur77 [94]. This
group scanned their library for compounds that could inhibit SPI-1 secretion by SDSPAGE analysis. Treatment of bacteria with cytosporone B also prevented the SPI-1dependent invasion of HeLa cells. Its potency was in the low micromolar range,
comparable to most other reported T3S inhibitors. By RT-PCR analysis, they found that
it acted upstream of HilD and HilA, up-regulating the nucleoid proteins Hha/H-NS that
inhibit their expression. By up-regulating inhibitors of the SPI-1 regulators, cytosporone
B down-regulated the expression of SPI-1 genes to inhibit type III secretion in
Salmonella.
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Table 1.3 Summary of other T3SS inhibitors and their reported inhibitory activities.
Specific bacterial effectors antagonized by the inhibitors are noted in parentheses.
Representative compounds

1

Regulation

Secretion/Translocation

T3SS
IC50

Infection

Other
Pathways

S. typhimurium (SipA,
SopE)

Cl

Ref
44

NH
HO2C

O

P. aeruginosa (ExoU)

CF3
N

N

P. aeruginosa:
Inhibits exoT
transcription

2
Cl

O
H
N

O ∗

Y. pestis (YopE-βla)

O

O

Cl

3

P. aeruginosa

C15

C24
HN

O
S
S
N
H

N

N

O

OH

Y. pseudotuberculosis:
No effect on
needle
assembly

Y. pseudo-tuberculosis:
Prevents translocation of
YopE-βla

EPEC: No
effect on
OmpA level

Y. pestis

12.5 µM
for
ExoS

P. aeruginosa: Inhibits
ExoU-dependent CHO
cytotoxicity

22 µM
for
YopE

C. trachomatis:
Inhibits growth in
Hep-2 cells
P. aeruginosa:
Reduces Hep-2 cellrounding by

P. aeruginosa

P. aeruginosa:
No effect on
type IImediated
elastase
secretion

80

Y. pseudotuberculosis:
Increases Yop
leakage, and
C20 reduces
adherence of
Hep-2 cells

51

N

N

N

C20

4

Compound 1
N
HO

OH
HO2C

S

N

Y. pestis: Prevents
translocation of YopE-βla

10 - 15
µM for
Yops

Y. pestis: Reduces
HeLa cell toxicity

81

S

EPEC (Tir)
N

H
N

N

H
N
O

O

N

N

N

HO2C

N

NH

NH

S

Compound 2

5

S. typhimurium (SipB)

20 - 80
µM for
SipB

P. aeruginosa (ExoU)

>100
µM for
ExoU

N

82

N
Cl

N
N

N
N

N
H

OH
O

P. aeruginosa: No effect on
T3S secretion

6
O

NH2

Y. pseudo-tuberculosis

7
O
NH
O2N

83

Inhibits ExoUmediated killing of
Saccharomyces
cerevisiae

Pseudolipasin A

N

P. aeruginosa:
Protects CHO cells
and Dictyostelium
discoideum, from
ExoU cytotoxicity

O
N

N
OH

28

Y. pseudotuberculosis: Reduces
macrophage
cytotoxicity and
increases mouse
survival

85

Table 1.3 continued.
Representative compounds

8

O

O

O

HN

N

N

T3SS
IC50

Infection
Y. pestis: Reduces
mammalian cell
cytotoxicity

N

Other
Pathways
Inhibits
ATPase
activity of
BsaS protein
from
Burkholderia
mallei

Ref

Y. pestis (YopE)

20 µM

EPEC (EspB)

20 µM

EPEC

20 nM in
hemolysis
assay

EPEC: Prevents
hemolysis of
erythrocytes

89,
91

EPEC (EspA, EspB,
EspD)

1.5 µg/ml in
hemolysis
assay

EPEC: Prevents
hemolysis of
erythrocytes

92

N
H

S

H
N

O

Secretion/Translocation

O

O

O

O

Regulation

86

O
N
H

O

N

S

9

EPEC: No effect
on type-V
effector EspC

OH
HO
O

OH

OH

OAc O

87,
88

O

OH O

HO

O

O

O

OH

O

OH

O

O

OH

O

Caminoside A

10
OH

NH2

OH

O

H
N

N
H

HN2OC N
NH

NH2 O

OH

CO2H

HN

Guadinomines

11
OH
HO

MeO

H

O

N

O

OH

H

EPEC: No effect
on expression of
GroEL

O

NH

Citrobactor
rodentium Protects
mice from
infection

OH
O

O
HO
HO

Aurodox
S. typhimurium:
down-regulates
HilD, HilA, and
effectors

12
OH

O

S. typhimurium

HO
O

O

Cytosporone B

29

S. typhimurium:
Prevents invasion
of HeLa cells

93

1.5 Additional assays for monitoring T3SSs
To facilitate the analysis of T3SSs and small molecule inhibitor discovery, new
assays have been developed to more efficiently and precisely visualize protein secretion
and translocation. Our laboratory recently described a carboxypeptidase G2 (CPG2)based reporter system for fluorescence and visible detection of type III protein secretion
from Salmonella (Fig. 1.5B) [50]. The orthogonal specificity of CPG2 presents an
attractive enzyme-reporter system to monitor bacterial protein secretion. CPG2 is a 43
kDa metalloprotease found in rare Pseudomonas syringae strains that selectively cleaves
glutamate (Glu) from small molecule metabolites [95]. Importantly, the glutamylcarboxypeptidase activity of CPG2 is not present in most species of bacteria or higher
eukaryotes. The ability of CPG2 to hydrolyze urea analogues of Glu provides a unique
enzymatic activity to uncage fluorogenic dyes. Based upon the tunable, photostable, and
fluorescent

properties

of

2-dicyanomethylene-3-cyano-2,5-dihydrofuran

(CyFur)

fluorophores [96-98], a Glu-modified derivative of CyFur (Glu-CyFur) was synthesized
as a potential fluorogenic substrate for CPG2. The time-dependent uncaging of GluCyFur with CPG2 can be readily observed by the naked eye with or without UVexcitation. In S. typhimurium, SopE2-CPG2-HA was cloned into the pWSK29 plasmid
driven by the SopE2 promoter. S. typhimurium deficient in a structural component of the
SPI-1 T3SS needle complex (∆invΑ) did not secrete SopE2-CPG2-HA and,
consequently, did not exhibit CPG2 activity in the growth media, confirming that this
assay measures secretion through the T3SS.
The SopE2-CPG2-HA:CyFur reporter system can differentially measure the
activity of T3SS inhibitors. An INP-0007 analog lacking the dibromophenol motif
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showed no inhibitory activity as compared to INP-0007, which suggests that the
dibromophenol motif of INP-0007 is crucial for potent inhibition of T3SSs. Moreover,
INP-0007 is ~4 times more potent in blocking SopE2-CPG2-HA secretion than 2-imino5-arylidene-thiazolidinone with IC50 values of 5.5 and 22.6 µM, respectively. These
experiments highlight the utility and sensitivity of the CPG2:Glu-CyFur reporter system
in measuring differential inhibitory activity of small molecules targeted at T3SSs. The
CPG2:Glu-CyFur reporter system provides a robust and sensitive method for monitoring
protein expression and secretion. This system is complementary and orthogonal to other
enzyme reporter systems such as luciferase and β-lactamase, making it potentially useful
for dual-imaging applications in the future.
Green fluorescent protein (GFP)-based systems have been employed to monitor
type III protein secretion. While direct translational fusions of GFP to bacterial effectors
have not been successful, GFP-labeled effector chaperones can be used as probes to
visualize translocation of bacterial effectors into the host cells (Fig. 1.5D). This approach
allows the imaging of effector accumulation in the cytosol of the host cells by detecting
clustering or accumulation of the fluorescently labeled chaperones. Schlumberger et al.
used this strategy to monitor the injection of the Salmonella effector SipA into the host
cytosol and concurrent depletion from the bacterial cytosol in real time [52].
Alternatively, Palmer and co-workers recently reported a split GFP system to image T3S.
They fused the small 13-amino-acid 11th strand of the GFP β-barrel to Salmonella
effectors and expressed the complementary fragment of the split GFP in trans in the host
cells (Fig. 1.5E) [53]. Upon T3SS effector translocation, the association of the two split
GFP fragments leads to fluorescent tagging of the effector population in the host cells.
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The authors used this method to directly label and visualize the dynamics of the T3SSdependent SPI-2 effectors PipB2, SteA, and SteC during bacterial replication in host
cells. Rather than GFP-based systems, smaller protein tags such as tetracysteine
sequences can also be used with fluorescein-based biarsenical dye FlAsH to image
bacterial effector translocation into mammalian cells (Fig. 1.5F) [54-56]. It would be
interesting to employ these assays to evaluate the precise effects of the reported T3SS
inhibitors on bacterial effector translocation into mammalian cells.

1.6 Identifying the target of the SAHs in Salmonella typhimurium
Though there has been much focus recently on T3SSs as potential therapeutic
targets, clear mechanisms of action for inhibitors of T3S are still lacking. The SAHs were
the first class of T3SS inhibitors reported and are one of the most potent to have broadspectrum inhibitory activity (Table 1.1). There are several reports on the activity of
SAHs in various pathogens and reports on in vivo activity, but though target identification
is an important step for drug development, no clear mechanism of action exists. The
potential for the SAHs makes them an attractive class to study, so we set out to identify
their molecular targets and determine their mechanism of action in Salmonella
typhimurium.
Salmonella is a Gram-negative pathogen that affects millions of people each year
[71,99-102] and causes gastroenteritis in a variety of hosts and typhoid fever in humans
[99]. Hosts become infected after ingesting contaminated food or water. Pathogenic
strains of Salmonella are able to establish infection by evading host defenses in the gut
and invading intestinal epithelial cells [99]. Once the bacteria have successfully invaded
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the host, they migrate to macrophages and reside in a special compartment called the
Salmonella containing vacuole (SCV). While in the SCV, the bacteria are able to avoid
degradative enzymes and gather nutrients to replicate and disseminate to other tissues
[99]. There are two Salmonella pathogenicity islands (SPI-1 and SPI-2) that encode for
virulence factors required for bacterial invasion and subsequent replication, respectively
[99]. Both loci encode proteins for type III secretion systems (T3SSs), which are essential
components of bacterial infections in vivo [30]. Upon contact with host cells, Salmonella
injects effector proteins through the T3SS into the host cytosol, where these bacterial
effector proteins alter host cell signaling to establish and propagate infection.

1.7 Strategies for target identification of small molecules
Given the potential utility of inhibiting T3SSs, our aim was to identify the targets
and determine the mechanism of action of the SAHs, one of the most potent classes of
inhibitors of T3S with broad-spectrum reactivity. The gold standard for target
identification of antibacterials is selecting for mutants that are resistant to small molecule
treatment and using sequencing techniques to discover what confers resistance [103,104].
Since anti-virulence compounds do not affect bacterial viability, there is no easy way to
select for resistant mutants because resistance does not confer any competitive advantage.
So although genetic strategies are very powerful for target identification, sequencing
resistant mutants does not apply in this case due to the inability to select for them.
Another commonly used approach for target ID of small molecules is affinity
chromatography [105,106]. Small molecules are attached to an affinity matrix and
immobilized. The matrix is then exposed to cell lysate so that the protein targets can bind
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the small molecule. Proteins that do not bind will be washed away, and the proteinbinding partners can be eluted by competition with active compound or a physical
perturbation such as heating. The eluted proteins can be identified by MS-based methods,
including quantitatively [107-109], to generate a list of potential targets. The targets must
be validated as binding-partners and confirmed to play a role in the phenotype observed.
For example, Ito and co-workers used an affinity chromatography strategy to identify the
target(s) of the drug thalidomide [105]. Thalidomide is a drug used to treat leprosy and
multiple myeloma, but it is also the causative agent of birth defects. They chemically
modified it and conjugated it to beads to pull down its targets from HeLa cell extracts.
After washing, they eluted the bound proteins by adding free thalidomide and separated
them by SDS-PAGE. Two proteins were identified by mass spec, and when
recombinantly expressed, only one of them bound to the beads: CRBN, which exhibits
ubiquitin ligase activity. Using a zebrafish model, they demonstrated that adding zCRBN
mRNA could rescue the developmental defects observed with thalidomide treatment.
A major drawback to the affinity chromatography method is that attaching a small
molecule to a bulky affinity matrix can be synthetically challenging and potentially
render the molecule inactive. There can also be high background from non-specific
interactions with the matrix. Apart from losing activity due to the small molecule
modification, potentially the biggest drawback is that the molecule binds proteins in an
unnatural environment. Proteins can lose their activity or specific interactions after lysis,
and solubility is a concern, especially for membrane proteins.
Because T3S is a dynamic process occurring inside cells, we would like to use
live cells in their natural environment for our targeting approach as opposed to cell lysate.
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The T3SS is a large protein complex that spans the bacterial membranes [30], so
maintaining its integrity when looking at inhibitors of the process it performs could be
essential for discovering the inhibitors’ target(s). Given that we can not use the classic
genetic approach, chemical methods are more suitable, but there are major disadvantages
to the standard affinity chromatography. The criteria for our strategy are as follows:
• We use a small chemical modification that allows the molecule to retain its activity.
• We use live cells because we are looking at inhibitors of a dynamic process.
• We have the ability to pull down membrane proteins.
Given these criteria, our focus is to create a cell-permeable molecule that retains its
inhibitory activity in cells and allows for retrieval of proteins following cell lysis,
including membrane proteins.
A bioorthogonal labeling strategy is ideally suited for this type of problem (Fig.
1.6). A bioorthogonal reaction is one that can occur exclusively between two groups
within a cellular environment. The two groups must be selective for each other and inert
to all other chemical reactions occurring in a cell. An example of a bioorthogonal
reaction is the Huisgen [3+2] Cu(I)-catalyzed azide-alkyne cycloaddition (CuACC),
which has been termed a “click chemistry” reaction [110]. The general strategy is that a
small molecule can be modified with an azide or an alkyne, which is a relatively small
modification, and incubated with cells. During the incubation, the small molecule reacts
with its targets or is incorporated onto its substrates as it would normally. After cell lysis,
a tag containing the corresponding reactive group can be selectively reacted with the
small molecule probe to detect its reactivity with proteins (Fig. 1.6A). The detection tag
can be a fluorophore for visualization or a biotin tag for selective retrieval and proteomic
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identification (Fig. 1.6B) [111,112]. This approach has been extensively used by our
laboratory and others, and there are several examples in the literature of azide- and
alkyne-functionalized chemical probes that allow for labeling of proteins in their native
cellular environments [113-118]. Major advantages of this technique are its orthogonality
to biological systems, relatively small chemical handle, efficiency, and ability to be used
in live cells [118]. These characteristics make it a valuable technique that is central to our
target identification strategy.
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Figure 1.6 Bioorthogonal labeling strategy. A) An alkyne chemical probe can be
incubated with cells and incorporated onto proteins. After lysis, the probe can be reacted
with an azide via the copper(I)-catalyzed azide-alkyne [3+2] cycloaddition with a
fluorescent tag for imaging and in-gel fluorescence or a biotin tag for retrieval and
subsequent proteomic identification. B) Structures of the azido-Rhodamine dye (az-Rho)
for imaging and the cleavable azido-biotin affinity tag for retrieval.
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New strategies for antibacterial development are necessary to combat the
emerging resistance among bacterial pathogens. Targeting bacterial virulence to treat
infection provides an opportunity to circumvent resistance mechanisms while leaving the
beneficial microbiota intact. There are several classes of small molecule inhibitors that
target various steps necessary for many bacterial pathogens to establish infection. The
SAHs are an interesting class of compounds that show significant promise as inhibitors of
T3SSs and bacterial virulence, but no clear mechanism of action hampers their
development. A bioorthogonal labeling strategy is a fitting approach for answering an
important question in the development of new antibacterials and validating an antivirulence approach.
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CHAPTER 2 – Efforts Towards Target Identification of the Salicylidene
Acylhydrazides

Abstract
The salicylidene acylhydrazides are a class of anti-virulence compounds that
block secretion of bacterial effector proteins through the T3SS and attenuate infection in
various species of Gram-negative bacteria; however, the molecular target(s) of these
compounds remains unknown, and the potency of these compounds is not optimal. To
discover the molecular targets of SAHs and their mechanism of action, I synthesized
alkynyl analogs and employed bioorthogonal labeling techniques for proteomic analysis
of their protein-binding partners. Through SAR analysis of alkynyl analogs, I discovered
important features for inhibitory activity of the SAHs and observed that they covalently
modify many proteins; however, the functional protein targets responsible for SAH
activity remain to be determined.
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Introduction

Type III secretion is an essential process for many bacterial pathogens to establish
infection [30]. It involves secreting effector proteins from the bacterial cytosol through a
molecular syringe called the type III secretion system (T3SS) into the host cell,
whereupon these effectors alter host cell signaling to establish and propagate infection
[30,99]. Due to the increasing rate of emerging antibiotic resistant bacteria, targeting type
III secretion has recently become an alternative “anti-virulence” approach for combating
infection [1,2].
A large-scale screen for inhibitors of type III secretion in Yersinia discovered a
class of compounds called the salicylidene acylhydrazides (SAHs) that were then found
to block type III secretion in various pathogens [48] (Table 1.1); however, the precise
target and mechanism of action of these compounds remains unknown. There are reports
characterizing their activity in Chlamydia [65-69], E. coli [62,63], Salmonella [50,70-72],
Shigella [73], and Yersinia [61], with studies suggesting the mechanism is through
transcriptional effects [62,66,68,72], iron restriction [68,72], or disrupting the needle
complex assembly [73]. Negative controls are lacking in some of these studies and
species to species variation renders the mechanism unclear. To find the direct target of
the SAHs, one study linked a compound to a solid support to pull down the non-covalent
protein-binding partners in E. coli [63]. No single target could explain the observed
phenotype for this class of compounds, and the authors concluded that the mechanism
was likely a polypharmacological effect disrupting the normal metabolism of the bacteria,
thus affecting their virulence. Since there is no clear consensus as to the mechanism of
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action for the SAH’s, we have taken a bioorthogonal approach to identify their protein
targets and elucidate their mechanism of action.

Results
2.1 Synthesis and biological activity of photocrosslinking alkynyl SAH
The initial parent compound (INP-0007) discovered from the screen in Yersinia
[48] contains a dibromophenol motif on one end of the molecule, which is important for
its inhibitory activity. Based on preliminary SAR analysis, the other end of the molecule,
however, appeared to be more tolerant to modification. We envisioned creating a
trifunctional probe that could be used to identify the protein targets of these compounds
[119]. By modifying the more tolerant side of the molecule with a photocrosslinker and
an alkyne, we could covalently bind the small molecule to its protein targets with UV
irradiation [120] and use the alkyne as a chemical handle to pull out the protein-binding
partners (Fig. 2.1). The alkyne can be selectively reacted with an azide via the copper(I)catalyzed azide-alkyne cycloaddition (CuAAC), or “click chemistry”, for visualization of
protein-binding partners using an azido-fluorophore or selective retrieval with an azidobiotin tag for proteomic identification [111,112] (Fig. 1.6).

41

Chemical handle!

O

Br
HO

O
N
H

N

Br
O

Br

HO

O
N
H

N

N

Br

N

O2N

INP-0007 (2.1)!

CF3

PC-alk-INP (2.2)!

Photocrosslinker!

Figure 2.1 Structure of a type III secretion inhibitor and a bioorthogonal
photocrosslinking analog. INP-0007 (2.1) can be modified to yield PC-alk-INP (2.2), an
analog containing a photocrosslinker and a chemical handle for target identification
studies.
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INP-0007 was synthesized in two facile steps as previously reported [121], and
PC-alk-INP (2.2) was synthesized by coupling the dibromophenol fragment with the
alkynyl photocrosslinking component as depicted in Figure 2.2. The alkynyl
photocrosslinking carboxylic acid (2.14) was synthesized according to published
procedure [122], and the dibromophenol fragment (2.15) was synthesized by reacting
hydrazine with 3,5-dibromosalicylaldehyde.
I first evaluated the activity of INP-0007 using a type III secretion assay in
Salmonella typhimurium. Bacteria were incubated in the presence of compound or control
for 4 hours. At the end of the incubation, the bacteria are spun down, and the proteins
secreted into the culture supernatant are precipitated, separated by SDS-PAGE, and
stained with Coomassie blue [71]. The majority of the secreted proteins are SPI-1
effectors, whose identities were confirmed by proteomic analysis of the Coomassiestained gels from wild type and a SPI-1 T3SS-deficient strain (∆invA) of S. typhimurium
(Fig. 2.3 and Table 2.1).
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Figure 2.3 Proteomic analysis of secreted SPI-1 effectors. Secreted proteins were
separated by SDS-PAGE and stained with Coomassie blue (CB). Bands were excised
from the gel, trypsinized, and analyzed by LC-MS/MS. Percent coverage is shown in
parentheses.

Table 2.1 Proteomic identification of secreted Salmonella proteins. A minimum of 2
unique tryptic peptides were used to assign protein bands. Accession numbers are from
the UniProtKB database.
WT

ΔinvA

Protein Name
Cell invasion protein sipA
Cell invasion protein sipB
Inositol phosphate phosphatase sopB
Flagellar hook-associated protein 1
Secreted effector protein sptP
Phase 2 flagellin
Flagellin
Flagellar hook-associated protein 2
Cell invasion protein sipC
Cell invasion protein sipD
Surface presentation of antigens protein spaN
Flagellar hook-associated protein 3
Phase 2 flagellin
Flagellin

Gene Name
sipA
sipB
sopB
flgK
sptP
fljB
fliC
fliD
sipC
sipD
spaN
flgL
fljB
fliC

Accession Number
Q56027
Q56019
O30916
P0A1J5
P74873
P52616
P06179
P16328
Q56020
Q56026
P40613
P16326
P52616
P06179
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Molecular Weight
(kDa)
74
62
62
59
60
53
52
50
43
37
36
34
53
52

% Coverage
71
65
73
71
54
56
75
80
90
75
63
79
65
73

Peptide Spectral
Counts
716
382
217
214
55
23
322
366
605
118
110
136
95
404

After confirming the activity of INP-0007 in this secretion assay, PC-alk-INP
(2.2) was tested. Unfortunately, PC-alk-INP was inactive likely due to the structural
modifications introduced (Fig. 2.4A). When the bacteria treated with PC-alk-INP were
lysed and reacted with azido-Rhodamine to evaluate the labeling profile, I observed an
unexpected result; even without UV irradiation of the photocrosslinker, this compound
covalently reacted with many proteins, suggesting something inherent in the structure of
PC-alk-INP was capable of forming covalent bonds without photo-activation (Fig. 2.4B).
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Figure 2.4 Secretion profile and protein labeling of T3SS inhibitor and PC-alk-INP
probe. A) INP-0007 (1) and PC-alk-INP (PC) were incubated with Salmonella for 4
hours at a concentration of 50 µM before the secreted proteins were precipitated,
separated by SDS-PAGE, and stained with Coomassie blue (CB). B) The bacterial pellet
was lysed, reacted with az-Rho, separated by SDS-PAGE, and analyzed by in-gel
fluorescence imaging.
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2.2 Synthesis and biological activity of alkynyl SAHs
Although the alkynyl photocrosslinking moiety rendered PC-alk-INP inactive, it
appeared that a photocrosslinker was unnecessary to label proteins covalently. This led
me to synthesize simpler alkynyl derivatives that did not contain the photocrosslinking
group. With just a small structural modification, perhaps the compound could still be
active and covalently bind its targets with a chemical handle intact. The larger alkynyl
photocrosslinking fragment could be replaced with one containing just a small alkynyl
group. As a negative control, the dibromophenol motif could be removed, and the
corresponding alkynyl negative control could be synthesized to rule out nonspecific
binding (Fig. 2.5).
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Figure 2.5 Structures of T3SS inhibitor INP-0007, a negative control (SAH-1), and their
corresponding alkynyl analogs for protein labeling studies.
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Initially, I synthesized three analogs of INP-0007 (Fig. 2.6): one without the
dibromophenol motif (2.16), which was shown to be the ‘business end’ of the molecule,
and an alkynyl analog for these two molecules (2.17 and 2.18). By precipitating the
proteins secreted into the supernatant of cultures incubated with compound, I confirmed
that the dibromophenol motif was essential for inhibiting type III secretion in S.
typhimurium and that appending an alkyne did not significantly affect activity (Fig. 2.7);
however, upon lysing the bacteria and performing the CuACC with azido-Rhodamine and
separating the proteins by SDS-PAGE, in-gel fluorescence analysis showed that the
active alkynyl analog 2.17 covalently modifies a large number of proteins while the
inactive analog 2.18 does not (Fig. 2.7D).
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Figure 2.7 Activity of SAHs in S. typhimurium. A) Scheme of alkynyl SAH 2.17
blocking type III secretion in Salmonella typhimurium. B) Structures of INP-0007 (2.1), a
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2.3 SAR analysis of alkynyl SAHs for inhibitory activity and covalent labeling
To determine the relevance of the covalent modification by the SAHs, I
synthesized a panel of alkynyl analogs (2.23-2.28, Fig. 2.8) to systematically address the
SAR of these compounds and correlate the covalent modification of proteins with
inhibition of secretion. The analogs were synthesized in the same manner as alk-INP,
using a different aldehyde in the final coupling step (Fig. 2.6). The panel of analogs
displayed a range of both inhibitory activity (Fig. 2.9) and covalent modification of
proteins (Fig. 2.10), but no correlation between the two was observed (Fig. 2.11). It is
interesting to note that having just a single bromine atom on the phenolic ring at either
the 3’ or 4’ position retains activity, while having no bromine at all decreases potency to
some extent, but one at the 5’ position completely abolishes activity. The phenol and the
hydrazone are both crucial to activity since capping the phenol with a methyl group or
reducing the hydrazone results in a loss of activity; however, the effects on inhibitory
activity do not correlate with the extent of covalent modification.
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Figure 2.8 Panel of alkynyl salicylidene acylhydrazide analogs synthesized.
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Figure 2.9 Effect of T3SS inhibitors and probes on SPI-1 effector secretion. Secreted
proteins in the culture supernatant of bacteria incubated with compound were precipitated
and separated by SDS-PAGE before staining with Coomassie blue (CB).
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Figure 2.10 In-gel fluorescence analysis of proteins labeled by alkynyl SAHs.
Bacteria were incubated with small molecule for 4 hours before the lysate was reacted
with azido-Rhodamine (az-Rho) and separated by SDS-PAGE. CB, Coomassie blue.
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The formation of a covalent adduct with a protein proceeds by at least two steps
and can be modeled using Michaelis-Menten kinetics. The general reaction scheme is
shown in Fig. 2.12, where the first step is a reversible noncovalent binding step that
forms an intermediate complex that allows for the subsequent covalent modification. The
initial rate of product formation V0, can be described as

(Eq. 2.1)

This is analogous to the Michaelis-Menten equation where using a steady-state
assumption, Vmax is the maximum rate of EI formation, [I] is the inhibitor concentration,
and Km equals (k2+k-1)/k1. Km is the concentration of inhibitor when V0 is one half Vmax
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and can be described as a lumped rate constant that relates product formation (k2) and
dissociation (k-1) of the intermediate EI* to its formation (k1).

E+I

k1
k-1

EI*

k2

EI

Figure 2.12 Reaction scheme for small molecule binding to proteins. An enzyme or
protein, E, and an inhibitor, I, form an intermediate, EI*, that can then go on to form the
covalent adduct, EI.

Given that we do not observe a significant difference in the profile of proteins
labeled by the alkynyl SAHs but only in the extent of modification (Fig. 2.10), there are a
few parameters that could explain these differences [123]. The relationship between the
rate constants k1, k-1, and k2 controls the level of covalent labeling observed for the small
molecule inhibitors. Only when the noncovalent complex EI* forms for a sufficient
amount of time can the chemical covalent modification occur. The noncovalent affinity
of an inhibitor for its target proteins is controlled by k1 and k-1, and it must be high
enough to allow for the k2-dependent covalent modification step to occur. Compounds
with high fluorescence labeling must have some combination of a high affinity for the
target proteins with a k2 large enough to permit covalent labeling during the residence
time of the noncovalent complex. Compounds with low labeling may have minimal
affinity for the target proteins, are less reactive, or a combination of the two. It is the
interplay between affinity and reactivity that dictates the extent of covalent modification.
It is also possible that the formation of the covalent adduct EI is reversible, and this
would also play a role in the observed labeling intensity.
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2.4 Effect of SAHs on Salmonella transcription
Since the SAHs react with many proteins, and there were previous reports of the
SAHs affecting transcription [62,66,68] in Salmonella [72], we performed transcriptional
profiling of virulence-related genes in cultures incubated with active (INP-0007 (2.1),
alk-INP (2.17), and alk-3’Br (2.26)) or inactive compounds (alk-SAH (2.18) and alk-5’Br
(2.24)). Genes involved in redox chemistry, iron homeostasis, SPI-1, and SPI-2 were
analyzed, but no correlation between activity and transcriptional responses was observed
(Fig. 2.13A). Using an effector-enzyme fusion protein assay developed in our laboratory
[50], an enzymatic readout can be used to determine the amount of fusion protein present.
While the parent compound 2.1 inhibits secretion of this fusion protein into the
supernatant, it does not affect its levels in the lysate (Fig. 2.13B). These results
demonstrate that transcriptional effects on virulence on a more global level and on a
single effector level are not correlated with inhibition of secretion.
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Figure 2.13 Effects of SAHs on expression of Salmonella virulence-related genes. A)
RT-PCR analysis from cultures incubated with active or inactive compounds (performed
by Angelica Ferguson). B) Percent CPG activity from SopE2-CPG2-HA effector-fusion
protein secretion and expression after incubation with INP-0007 as compared to DMSOtreated control.

2.5 Proteomic identification of SAH protein-binding partners
Since the SAHs contain an inherent covalent reactivity, we wanted to identify the
protein target(s) that are responsible for the observed phenotype. Although there was no
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correlation between overall levels of protein labeling and inhibitory activity, it is
possible, however, that it is not the overall extent of covalent modification that is
important for inhibitory activity, but instead modification of specific proteins. In order to
identify which proteins the small molecules modify, I performed a labeling and
enrichment assay followed by mass spectrometry for proteomic identification of the
alkynyl SAH targets (Fig. 1.6). Bacteria were incubated with compound before click
chemistry was performed on the lysate with an azido-azo-biotin tag [111,112].
Streptavidin resin was used to capture the biotinylated proteins, and the azobenzene
linker was cleaved using sodium dithionite to elute only the tagged proteins, leaving
behind any nonspecifically bound proteins. The eluted proteins were separated by SDSPAGE before trypsinization and analysis by liquid chromatography coupled with tandem
mass spectrometry.
We chose to identify alk-3’Br’s (2.26) protein targets because it showed the
highest inhibitory activity compared to its covalent reactivity, thus potentially simplifying
the results. In addition to a DMSO control, two inactive analogs that were at the extremes
of covalent labeling, alk-SAH and alk-5’Br (compounds 2.18 and 2.24), were also chosen
to rule out irrelevant hits (Fig. 2.11). The identification of the high-confidence hits (10x
DMSO sample and at least 10 spectral counts) for each sample is displayed in Table 2.2.
The majority of the protein hits were metabolic proteins that had no obvious link to the
observed phenotype. There were also no major differences in the protein-binding partners
for the active (alk-3’Br, 2.26) and inactive (alk-5’Br, 2.24) compounds, suggesting the
most abundant subset of covalently modified proteins is not responsible for inhibitory
activity.
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Table 2.2 High-confidence proteins pulled down by small molecule probes. Proteins
were identified with at least two unique peptide spectra, 10 spectral counts, and 10 times
the background.
Number of assigned spectra!
Identified Proteins
30S ribosomal protein S2
Cell invasion protein sipA
3-oxoacyl-[acyl-carrier-protein] synthase I
Glutathionine S-transferase
Transcription elongation factor greA
Protein csiD
Dihydrodipicolinate synthase
2-dehydro-3-deoxyphosphooctonate aldolase
Glyoxylate/hydroxypyruvate reductase A
Glutamate/aspartate transporter
Response regulator
2,3-bisphosphoglycerate-dependent phosphoglyce
Probable thiol peroxidase
Inositol phosphate phosphatase sopB
Putative oxoacyl-(Acyl carrier protein) reduct
Ribose-phosphate pyrophosphokinase
D-ribulose-5-phosphate 3-epimerase
Putative alcohol dehydrogenase
S-ribosylhomocysteine lyase
Cell division inhibitor
Putative intracellular proteinase
Phosphoserine aminotransferase
Flagellin
Sigma cross-reacting protein 27A
Putative oxidoreductase
L-threonine 3-dehydrogenase
30S ribosomal protein S5
Oxygen-insensitive NADPH nitroreductase
Peptidyl-prolyl cis-trans isomerase
ATP synthase subunit delta
ATP synthase subunit b
Amidophosphoribosyltransferase
Putative periplasmic protein
UDP-glucose 4-epimerase
1,4-alpha-glucan-branching enzyme
Protein hfq
Universal stress protein E
Putative diadenosine tetraphosphate
Cell invasion protein sipD

Accession #
P66541|RS2_SALTY
Q56027|SIPA_SALTY
Q7CQ97|Q7CQ97_SALTY
Q8ZPM7|Q8ZPM7_SALTY
P64281|GREA_SALTY
Q9FA43|CSID_SALTY
Q8ZN71|DAPA_SALTY
P65215|KDSA_SALTY
Q8ZQ30|GHRA_SALTY
Q7CQY9|Q7CQY9_SALTY
Q7CP63|Q7CP63_SALTY
Q8ZQS2|GPMA_SALTY
Q8ZP65|TPX_SALTY
O30916|SOPB_SALTY
Q7CQG2|Q7CQG2_SALTY
P0A1V6|KPRS_SALTY
Q8ZLK4|Q8ZLK4_SALTY
Q8ZM07|Q8ZM07_SALTY
Q9L4T0|LUXS_SALTY
Q8ZP10|Q8ZP10_SALTY
Q7CPQ5|Q7CPQ5_SALTY
P55900|SERC_SALTY
P06179|FLIC_SALTY
Q8ZLR6|Q8ZLR6_SALTY
Q8ZKX9|Q8ZKX9_SALTY
Q8ZL52|TDH_SALTY
P0A7W4|RS5_SALTY
Q9Z5Z2|NFSA_SALTY
Q8ZLL4|Q8ZLL4_SALTY
Q7CPE5|ATPD_SALTY
Q7CPE4|ATPF_SALTY
Q8ZNC2|Q8ZNC2_SALTY
Q7CQV7|Q7CQV7_SALTY
P22715|GALE_SALTY
Q8ZLG5|GLGB_SALTY
P0A1R0|HFQ_SALTY
Q8ZP84|USPE_SALTY
Q8ZM04|Q8ZM04_SALTY
Q56026|SIPD_SALTY

MW
27 kDa
74 kDa
38 kDa
22 kDa
18 kDa
37 kDa
31 kDa
31 kDa
35 kDa
27 kDa
27 kDa
28 kDa
18 kDa
62 kDa
28 kDa
34 kDa
24 kDa
42 kDa
19 kDa
30 kDa
19 kDa
40 kDa
52 kDa
23 kDa
21 kDa
37 kDa
18 kDa
27 kDa
21 kDa
19 kDa
17 kDa
57 kDa
33 kDa
37 kDa
84 kDa
11 kDa
36 kDa
17 kDa
37 kDa

DMSO
6
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

alk-5'Br alk-3'Br alk-SAH
36
60
45
16
27
23
20
21
15
14
24
10
10
15
11
14
18
8
15
13
9
14
17
6
13
8
10
10
9
8
8
11
11
10
11
7
8
8
11
6
15
6
7
9
13
11
12
5
13
15
0
8
12
0
7
10
8
4
11
10
6
10
11
12
9
3
5
10
6
10
12
0
10
8
4
8
11
0
4
10
6
7
11
6
9
11
0
7
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5
4
10
4
12
6
0
12
9
0
6
11
2
7
11
0
4
4
10
3
10
0
6
10
0
0
9
3

2.6 SAH inhibition of Salmonella invasion of HeLa cells
While the functional targets of the SAHs remains to be determined, I tested
whether the inhibitory activity of these compounds against protein secretion correlated
with preventing Salmonella invasion of host cells. HeLa cells were infected for 30
minutes at a multiplicity of infection (MOI) of 10 with Salmonella grown in the presence
of compound or DMSO, and the extent of invasion was determined using flow cytometry.
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The inhibition of effector secretion into the culture supernatant correlates well with
preventing Salmonella from invading HeLa cells, and by systematically investigating the
SAR of these compounds, I discovered an analog (alk-3’Br, compound 2.26) with greater
potency in an infection setting than the parent compound (Fig. 2.14).
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Fig 2.14 Effects of SAHs on Salmonella invasion of HeLa cells. Bacteria grown in the
presence of 50 µM compound or DMSO were used to infect HeLa cells for 30 min at an
MOI of 10. The percentage of infected HeLa cells was determined by staining with an
anti-Salmonella antibody followed by analysis with flow cytometry. The statistical values
from a two-sided Student’s t-test are as follows: *, P < 0.001; **, P< 0.0001.

Discussion
The salicylidene acylhydrazides are a well-studied class of anti-virulence
compounds that inhibit type III secretion in several bacterial pathogens; however, their
precise mechanism of action is unknown. By synthesizing a panel of SAH analogs
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displaying a range of inhibitory activity (Fig. 2.9), I identified key chemical features
important for activity. The analysis of these compounds in Salmonella suggests their
effects on transcription are not linked to their inhibition of type III secretion (Fig. 2.13).
The SAHs also covalently label Salmonella proteins, but the functional consequences of
these findings on their mechanism of action are still unclear (Fig. 2.10 and Table 2.2).
Nonetheless, my studies of the SAHs have stressed the importance of negative controls
and revealed a more potent compound at preventing Salmonella invasion of HeLa cells
(Fig. 2.14).
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CHAPTER 3 – The Repurposed Kinase Inhibitor H-89 Targets Bacterial Virulence
Pathways to Limit Infection

Abstract
The emergence of antibiotic-resistant bacterial pathogens has motivated new
approaches for antibacterial drug discovery that target virulence pathways or host
enzymes important for infection [1,2]. The isoquinolinesulfonamide H-89 was discovered
in a screen for host kinase inhibitors that blocked Salmonella replication in macrophages
[124]. The authors claimed that H-89 prevented bacterial replication through inhibition of
Akt, a host kinase activated during infection. H-89 did not affect the growth of the
bacteria in culture, and inhibition of Akt did not fully explain H-89’s effects, so we
hypothesized it could be acting as an anti-virulence compound. We discovered that H-89
inhibits the expression of S. typhimurium genes associated with bacterial virulence
including both SPI-1 and SPI-2 T3SSs. Since H-89 had a much larger effect on bacterial
replication than a potent and specific Akt inhibitor, my results suggest the effect of H-89
on bacterial virulence is the more relevant mechanism of action.
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Introduction
While several groups have specifically screened for compounds that inhibit type
III secretion system activity in liquid culture (Tables 1.1-1.3), screens for inhibitors in an
infection setting may reveal new lead compounds. Although this requires a more complex
screen, it bypasses several follow-up experiments that are necessary from evaluating
strictly bacterial systems. Hits from this type of screen are already known to be effective
in at least a cell culture system and not to be toxic to mammalian cells. In addition, since
many bacterial proteins are known to interact with host proteins, screening compounds in
an infection setting allows for discovering compounds that disrupt these important
pathogenic protein-protein interactions that would otherwise not be present in a screen
with only bacteria. Compounds that disrupt the host pathways hijacked by the bacteria
could also be effective for treating infection.
With more knowledge of host-pathogen interactions and the increasing need for
new antibacterial compounds, specifically targeting host pathways required for
pathogenesis is an alternative strategy. Chemical libraries previously developed for
mammalian targets are beginning to be repurposed for anti-infectives [125-127]. Notably,
Kuijl et al. conducted a whole-cell screen to identify host kinase inhibitors that could
block replication of Salmonella typhiumurium in macrophages [124]. This study showed
that the isoquinolinesulfonamide H-89 could effectively inhibit Salmonella replication
during infection without affecting bacterial growth in culture. A parallel siRNA screen
against host kinases on bacterial replication suggested the Akt1 network was crucial for
intracellular growth of Salmonella and Mycobacteria [124]. From these observations, the
antibacterial activity of H-89 was attributed to inhibition of Akt [124], a host kinase that
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is activated during Salmonella infection. However, a more potent and specific Akt
inhibitor failed to recapitulate the inhibition of bacterial replication in the same study
[124], suggesting an alternative mechanism of action for H-89 on intracellular bacterial
replication (Fig. 3.1).
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Figure 3.1 Structures and activity of isoquinolinesulfonamides on Salmonella and
Akt. A) Structures of inactive isoquinolinesulfonamide H-88 and active compound H-89.
B) Authors claimed isoquinolinesulfonamides prevented bacterial replication through
inhibition of host kinase Akt. Taken from [124].

Since H-89 did not affect the growth of Salmonella, and inhibition of Akt could
not fully explain its effect on bacterial replication, we hypothesized that it could be
inhibiting the virulence functions of the bacteria and represent a new scaffold for anti-
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virulence compounds. I therefore investigated its effects on bacterial virulence and type
III secretion function.

Results
3.1 H-89 inhibits bacterial replication through Akt-independent mechanism
To begin investigating the mechanism of action for H-89 on Salmonella
replication in mammalian cells, I compared the activity of H-89 and a more potent Akt
inhibitor on S. typhimurium replication in murine RAW264.7 macrophages. Following
entry into host cells, Salmonella replicates in a Salmonella-containing vacuole (SCV)
[99] and the extent of replication can be monitored by a standard gentamicin protection
assay. Briefly, RAW264.7 macrophages were infected with S. typhimurium for one hour,
at which point gentamicin was added to kill any remaining extracellular bacteria. H-89 or
other compounds were then added to infected macrophages and colony forming units
(CFUs) were determined 16 hours post-infection (pi) to determine the number of viable
intracellular bacteria. H-89, but not H-88, an analog that differs by one bromine atom
(Fig. 3.2A), significantly decreased the number of bacterial CFUs at 20 µM (Fig.3.2B),
which is consistent with published data [124]. However, a more potent and specific Aktinhibitor (Akti1/2) [128] displayed minimal inhibitory activity against Salmonella
replication compared to H-89 (Fig. 3.2B) even though the majority of active Akt in these
infected macrophages was depleted, as judged by Akt phosphorylation at Ser473 (Fig.
3.2C). Phosphorylation at this site is required for full activation of Akt and its
downstream signaling events [128]. These results demonstrate that pharmacological
inhibition of Akt is not sufficient for preventing bacterial replication. In addition, as
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reported by Kuijl et al., H-89 did not have any major effect on Salmonella growth in
liquid culture (Fig. 3.2D) [124], demonstrating this compound does not kill the bacteria
directly. These experiments suggest an alternative mechanism of action for H-89 on
Salmonella replication in host cells that is independent of Akt inhibition.
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Figure 3.2 H-89 inhibits bacterial replication through Akt-independent mechanism.
A) Structures of isoquinolinesulfonamides H-88 and H-89 and Akt inhibitor Akti1/2. B)
CFU numbers of intracellular Salmonella 16 hours pi. Compounds were added at 20 µM
after 1 hour of infection at an MOI of 5. The statistical value from a two-sided Student’s
t-test is as follows: **, P<0.001. C) Western blots of phospho-Akt (Ser473) and total Akt
levels 8 hours pi in infected macrophages with 20 µM compound treatment. NI, not
infected; WB, Western blot. D) Growth curves of Salmonella grown in the presence of
compound. Bacteria were incubated with H-89 (20 µM) or DMSO and OD600 readings
were taken every 30 minutes.
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3.2 H-89 inhibits expression of Salmonella virulence genes required for bacterial
infection
Since genetic and biochemical studies have shown that T3SSs are essential for
infection but do not affect bacterial viability in culture [30,99], we performed targeted
transcriptional profiling of S. typhimurium virulence factors to identify the potential mode
of action for H-89. For genes involved in redox chemistry or iron transport/acquisition,
no significant effect was observed for either H-88 or H-89 (Fig. 3.3A). In contrast, H-89
selectively decreased the expression of key S. typhimurium virulence factors required for
bacterial replication in macrophages. SPI-2 effector genes: sifA, sseJ, and sseC were
down-regulated along with SPI-1 T3SS components: regulator hilA, effector protein sipA,
and needle complex components invA, invG, and prgI (Fig. 3.3A). To determine if the
decreased levels of SPI-2 effector genes indeed affected protein levels, we evaluated the
expression of an HA-tagged SPI-2 effector (SseJ-HA) under the control of its native
promoter. Consistent with the transcriptional profiling data, SseJ-HA levels by Western
blot analysis were decreased when incubated with H-89 compared to the inactive H-88
control and DMSO (Fig. 3.3B). These results suggest that H-89 selectively downregulates several virulence genes involved in S. typhimurium T3SS-dependent invasion
and replication.
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Figure 3.3 Compound effects on gene expression. A) RT-PCR analysis of bacterial
cultures treated with 20 µM of compound (performed by Angelica Ferguson). B) Western
blot of SseJ-HA in the lysate of compound-treated cultures. WB, Western blot; CB,
Coomassie blue.

3.3 H-89 decreases the levels of bacterial effectors secreted during S. typhimurium
replication in host cells
Given the inhibition of bacterial replication and down-regulation of SPI-2
virulence genes in vitro, I investigated the effect of H-89 on intracellular levels of SseJ, a
SPI-2 effector that is secreted during Salmonella replication in macrophages. SseJ is a
key SPI-2 effector that exhibits phospholipase A and acyltransferase activity and opposes
the function of SifA, another SPI-2 effector responsible for establishing and maintaining
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the SCV in host cells [129,130]. To monitor the amount of SseJ secreted into the host
cytosol during infection, I used an S. typhimurium strain expressing SseJ-HA. By
immunofluorescence confocal microscopy, SseJ-HA was not observable in the host
cytosol until about 4-5 hours pi and became robustly seen 7 hours pi. I therefore
administered the compounds at 5 hours pi, and after a 2-hour incubation with compounds,
S. typhimurium-infected macrophages were permeabilized, fixed, and stained to examine
the amount of intracellular S. typhimurium and SseJ-HA. The H-89-treated samples
showed a marked reduction in the amount of SseJ-HA staining, while no apparent effect
on SseJ-HA expression or distribution was observed with 20 µM of the H-88 control
(Fig. 3.4). These results demonstrate that H-89 inhibition of SPI-2-associated virulence
factor expression also results in reduced levels of SPI-2 protein effectors such as SseJ
during S. typhimurium infection of host cells.
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Figure 3.4 Imaging of SseJ-HA during Salmonella infection. RAW264.7 macrophages
were infected for one hour (MOI = 1), and compound was added 5 hours pi. At 7 hours
pi, cells were fixed and stained with TO-PRO (blue), anti-Salmonella (green), and antiHA (red). Shown are representative images from three independent experiments.

3.4 H-89 also antagonizes the SPI-1 T3SS and inhibits Salmonella invasion of
epithelial cells
As the transcriptional profiling data suggests H-89 also inhibits expression of S.
typhimurium genes associated with the SPI-1-dependent invasion of host cells (Fig.
3.3A), I tested whether H-89 also impairs SPI-1 T3SS-associated functions. To validate
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our SPI-1 gene expression data, I employed an effector-enzyme fusion reporter system,
SopE2-CPG2-HA, for sensitive detection of type III protein expression and secretion in
S. typhimurium previously developed by our laboratory [50]. For this effector reporter
system, carboxypeptidase G2 (CPG2) is translationally fused to the S. typhimurium
effector SopE2 under control of its native promoter. By monitoring the enzymatic activity
of CPG2 with a fluorogenic substrate, this assay provides a visible and quantitative
method for determining effector protein expression and secretion [50]. Using this assay,
H-89 decreased the levels of SopE2-CPG2-HA in S. typhimurium cell lysates and in the
supernatant in a dose-dependent manner (Fig. 3.5A). The decreased level of secretion
correlates with the inhibition of protein expression observed in the cell lysate. The
inhibitory activity of H-89 can also be readily observed visually with the SopE2-CPG2HA system (Fig. 3.5B).
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Figure 3.5 H-89’s decrease of secreted effectors correlates with inhibition of
expression. A) SopE2-CPG2-HA secretion and expression were monitored using a
fluorescent readout from the supernatant and lysate, respectively. Samples incubated with
H-89 were compared to a DMSO control. B) Visual color change in the supernatant and
lysate samples from bacteria incubated with H-89.

I then evaluated the effect of H-89 on endogenously expressed SPI-1 effectors
that are secreted in S. typhimurium growth media. Coomassie staining of S. typhimurium
effector proteins secreted into the culture supernatant demonstrated that H-89 reduced the
amount of secreted SPI-1 effector proteins while the inactive analog H-88 had no effect
72

(Fig. 3.6A). Other Akt-selective inhibitors (MK2206 and Akti1/2) [128,131,132] and
another compound reported to prevent bacterial replication and inhibit Akt (AR-12) [133]
had no activity towards inhibiting SPI-1 effector protein secretion (Fig. 3.6A). Additional
broad-spectrum host kinase inhibitors (rottlerin and Sutent) [132,134] likewise did not
affect secretion of SPI-1 effector proteins (Fig. 3.6B). The inhibitory activity of H-89 was
dose-dependent up to a concentration that had no effect on bacterial growth and was more
potent than the previously reported T3SS inhibitor INP-0007 [48,71] (Fig. 3.7).
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Figure 3.6 Levels of secreted SPI-1 effectors in bacterial culture supernatants. A, B)
Bacteria were incubated with compound for 4 hours before secreted proteins were
precipitated, separated by SDS-PAGE, and analyzed by Coomassie blue (CB) staining.
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Figure 3.7 Dose-dependent decrease of secreted SPI-1 effectors. Bacteria were grown
for four hours in the presence of compound before proteins precipitated from the culture
supernatant were separated by SDS-PAGE and analyzed by Coomassie blue (CB)
staining. H-89’s potency was compared to the previously reported T3SS inhibitor INP0007.

To determine whether this pharmacological reduction of secreted SPI-1 effectors
could attenuate infection, I evaluated the effect of H-89 on S. typhimurium invasion of an
epithelial cell line. Flow cytometry with anti-Salmonella antibody staining was used to
quantify the number of S. typhimurium-infected cells (Fig. 3.8). Consistent with the
reduction of SPI-1 effector data (Fig. 3.3A and 3.6A), incubation of S. typhimurium with
H-89 also inhibited S. typhimurium invasion of HeLa cells, whereas H-88 had no
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significant effect (Fig. 3.8). These results demonstrate that H-89 can also inhibit SPI-1
T3SS function and attenuate S. typhimurium entry into epithelial cell lines.
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Figure 3.8 H-89 blocks S. typhimurium invasion of HeLa cells. HeLa cells were
infected at an MOI of 10 for 30 minutes with Salmonella that was grown in the presence
of compound. Experiments were done in triplicate and the number of infected cells was
measured using flow cytometry. NI, not infected. The statistical values from a two-sided
Student’s t-test are as follows: *, P < 0.01; **, P< 0.0001.

Discussion
Bacterial pathogens continue to be a global health problem, which necessitates
new strategies and antibacterials to combat infections. With the emergence of more
antibiotic-resistant bacterial strains, targeting host pathways and bacterial virulence
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mechanisms have become attractive strategies for counteracting and limiting drug
resistance [1,2]. As host kinases are often hijacked for bacterial infection, the repurposing
of kinase inhibitors may be an effective starting point for identifying new antibacterials
[135,136]. Indeed, a chemical and siRNA screen against host kinases by Kuijl et al. has
suggested the Akt kinase network may provide viable targets for limiting bacterial
replication in host cells and even demonstrated that H-89, a reported PKA-inhibitor can
block Salmonella and Mycobacteria replication in macrophages [124,137]. However, this
study also reported that a more potent and specific Akt-inhibitor had less of an effect on
bacterial replication [124]. Additionally, other H-89 analogs significantly inhibited
Salmonella replication with only a small effect on Akt activity [124], suggesting Akt is
not the primary target of H-89 to inhibit bacterial replication. Consistent with these
observations, I found that H-89 is about 30-40 times more effective than an Akt-specific
inhibitor (Akti1/2) at preventing Salmonella replication in macrophages (Fig. 3.2B) even
though Akti1/2 completely depletes the active population of Akt (Fig. 3.2C). This
demonstrates that pharmacological inhibition of Akt does not account for H-89’s activity
on bacterial replication. Taken together, these data suggest an alternative mechanism of
action for H-89 on inhibition of bacterial replication.
As bacterial pathogens like Salmonella turn on specific virulence pathways for
infection that are not required for growth in vitro, we evaluated whether H-89 impairs
Salmonella virulence mechanisms. We initially focused on T3SSs since these protein
secretion systems are essential for establishing and propagating Salmonella infection
[99]. Our targeted transcriptional profiling data demonstrated that H-89 decreased the
expression of genes associated with Salmonella virulence, including T3SS factors
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responsible for bacterial invasion and replication, while genes involved in redox or iron
homeostasis were not significantly affected (Fig. 3.3A). I further validated the impact of
H-89 on S. typhimurium virulence factors by demonstrating this brominated
isoquinolinesulfonamide impairs the expression (Fig. 3.3B) and consequently the
secretion of a SPI-2 effector (SseJ) during bacterial infection of macrophages (Fig. 3.4).
In addition to SPI-2 components responsible for Salmonella replication in host
cells, H-89 reduced the expression of SPI-1 T3SS components associated with bacterial
invasion (Fig. 3.3A). Notably, H-89 also diminished the secreted levels of SPI-1 effectors
into the bacterial culture media, whereas the inactive analog H-88, Akt-specific
inhibitors, and other promiscuous kinase inhibitors had no effect (Fig. 3.6A and 3.6B). H89 was also slightly more potent than the previously described T3SS inhibitor INP-0007
(Fig. 3.7) and effectively blocked S. typhimurium invasion of epithelial cells (Fig. 3.8).
Taken together, our results demonstrate that while H-89 does not affect bacterial growth,
it inhibits key virulence pathways in Salmonella. By inhibiting the expression of
virulence factors involved in both the initial and later stages of infection, H-89 can
prevent the T3SS-dependent invasion and replication of S. typhimurium. Disrupting
bacterial virulence rather than inhibiting Akt more likely explains the activity of H-89 on
bacterial replication.
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CHAPTER 4 – Discussion and Future Outlook

Developing anti-virulence compounds as an alternative to traditional antibiotics is
an attractive and promising strategy to combat the emerging antibiotic resistance we are
experiencing today [1,2]. The rate at which new antibiotic resistance is observed is
alarming compared to development of new antibiotics. If we were to continue on this
path, we would be at risk of reverting to a pre-antibiotic era, which would be devastating
to human health. Therefore, it is necessary to develop alternative approaches to
circumvent this pressing issue. An anti-virulence strategy that specifically targets
pathogenic bacteria falls into this category and also has the added benefit of leaving the
normal commensal microbiota largely intact. As we learn more about the relationship
between commensal bacteria and humans, we are realizing their importance in preventing
infection and stimulating the immune response [5,7]. It is also hypothesized that antivirulence compounds would apply less selective pressure for developing resistance, so
this could be a longer-term solution for battling bacterial pathogens. Support for this
claim comes from the fact that resistance is often transferred from commensals to
pathogens via horizontal gene transfer [3]. Resistance mechanisms develop due to
random mutations that yield a competitive advantage and are thus selected for, but since
the commensals would be generally unaffected by virulence inhibitors, they would be
less likely to aid the pathogenic bacteria in evolving resistance. The current state of
antibiotics emphasizes the need for alternative approaches to keep bacterial pathogens at
bay, and the advantages of targeting virulence mechanisms make it a promising strategy
moving forward.
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The discovery of T3SSs as essential mechanisms of bacterial virulence has
provided important and exciting targets for antibacterial development to address the
shrinking arsenal of antibiotics. Consequently, many new classes of small molecules have
been reported with inhibitory activity against T3SSs (Tables 1.1-1.3). Despite the
attractiveness of these potential anti-virulence compounds, none of the currently reported
T3SS inhibitors have advanced into the clinic. Major challenges still need to be addressed
before these compounds can be effective therapeutics. Notably, nearly all of the T3SS
inhibitors discovered from HTS cell-based assays have limited potency and lack clear
targets and mechanisms of action. For example, the preliminary studies of previously
described salicylidene acylhydrazides and thiazolidinones yielded structural features for
blocking the activity of T3SSs, but none of ~120 new analogs yielded more potent
inhibitors. Even though tethered thiazolidinone derivatives [78] and peptidefunctionalized analogs [77] have yielded improved inhibitory activity towards T3SSmediated invasion in vitro, the activity of more potent second generation thiazolidinones
(~56) in cell culture or animal models of bacterial infection have not been reported.
Anti-virulence compounds present a unique problem for identifying the targets of
these antibacterial compounds. Since they do not kill bacteria directly, the standard
antibiotic resistance selection strategy does not apply; bacterial viability needs to be
dependent on resistance. A potential alternative for target identification of anti-virulence
compounds is an infection-based selection strategy. Mutagenizing the bacteria and
infecting cells in the presence of compound could be a way to tie bacterial viability to
some level of resistance. If the compound is used at a high enough concentration where
only a small percent of bacteria survive, those bacteria can be plated and used to re-infect
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another batch of cells. Over several rounds of serial infections, any competitive
advantage that exists will be selected for, and a decrease in the compound’s efficacy
would be observed. Repeating the infections and increasing the compound’s
concentration will apply more pressure to develop resistance, and should resistant
colonies arise, they could be sequenced to uncover the mutation(s) that confer resistance.
This strategy is unlikely to work with compounds that have multiple targets, so
compounds exhibiting polypharmacological effects might not be suitable for such an
approach.
The salicylidene acylhydrazides were the first class of compounds discovered to
inhibit type III secretion [48]. Being active against several Gram-negative pathogens
made them an appealing class of anti-virulence compounds, and though several groups
have studied them, no clear mechanism exists for how they exert their inhibition. We
took a bioorthogonal approach to identify their target(s) and mechanism of action. By
inserting an alkyne onto the part of the molecule tolerant to modification, we made a
panel of bioorthogonal derivatives that taught us about the SAR of this class and provided
us with several negative controls for follow-up assays. Similar to the study by Wang et al.
[63], we pulled down many metabolic enzymes (Table 2.2) using our labeling and
enrichment strategy, which could suggest that the mechanism is due to a
polypharmacological effect that disrupts metabolism and dis-regulates virulence without
affecting growth. We learned that the SAHs have an inherent covalent reactivity, but
subsequent experiments cast doubt on the relevance of the covalent-binding partners’ role
in inhibiting type III secretion. This is important to keep in mind when thinking about
their potential clinical application and possible side effects.
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In general, I believe bioorthogonal labeling is a powerful method and can be an
effective strategy for target ID, but there are several things to keep in mind when using
this approach (Fig. 1.6). First, it is very useful for identifying the covalent-binding
partners of a small molecule – non-covalent interactions require a different workflow.
Ideally, the compound of interest would have a small number of protein-binding partners
to simplify the analysis and limit the number of potential targets. Another important
aspect is the necessity for negative controls. Though this is not exclusive to bioorthogonal
labeling strategies, they are essential for ruling out non-specific interactions and were a
key component of my studies with the SAHs.
Another issue that arises for inhibitors of T3SSs is that they need to be effective at
several stages of infection and be able to reach the relevant compartments. For example,
Salmonella typhimurium has two stages of infection, the initial invasion stage and the
subsequent replication stage, and both require a T3SS [99]. Once the bacteria
successfully invade host cells, they reside in the SCV while replicating and spreading. It
is quite possible that compounds can antagonize T3S activity in culture but are unable to
reach the bacteria during infection or only inhibit the initial stage of infection. Many of
the compounds discovered thus far are from HTSs that specifically look for inhibitors of
this first stage of T3S. While setting up a HTS of this nature is easier, in a clinical setting,
this would not be the relevant phase to be targeting. For example, the SAHs inhibit only
the initial stage of infection and for the most part require pre-incubation to see an
inhibitory effect, so from a clinical perspective, they might not be as useful. While T3SS
inhibitors

present

promising

leads

for

antibacterial

improvements in their potency are needed for clinical studies.
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development,

significant

Beyond in vitro screening of T3SS inhibitors, the analysis of small molecules that
inhibit bacterial virulence in more complex cell culture systems or animals could reveal
new classes of compounds and also begin to address their activity on host cells. For
enteric pathogens, it will be interesting to assay compounds targeting the bacterial
replication cycles in mammalian cells. These compounds may serve as better drug
candidates to treat systemic infection rather than anti-virulence compounds that may only
be used to prevent infection. Alternatively, analysis of compounds in small animal
models such as worms [138-140] and zebrafish [141] are already beginning to reveal
potential anti-virulence inhibitors as well as potential mechanisms of drug tolerance.
While this approach may yield compounds that activate host immunity [142], this
strategy may already select for compounds that can access the appropriate sites and
tissues relevant for bacterial infection in vivo and provide promising leads for clinical
development in humans.
The isoquinolinesulfonamide H-89 is an example of a compound that was
discovered in a screen using an infection setting [124]. The goal of the study was to find
compounds that block Salmonella replication during infection. The authors attributed the
activity of H-89 on bacterial replication to inhibition of the host kinase Akt. In agreement
with our findings, they also reported that a more potent and specific Akt inhibitor did not
have the same inhibitory effect as H-89, but they believed it was because H-89 targeted
other host kinases. Since they had only shown H-89 does not affect the growth of the
bacteria in culture, we examined whether H-89 affects the virulence properties of the
bacteria. Our data show that H-89 down-regulates genes involved in bacterial virulence
and impairs the T3SS-dependent invasion and subsequent replication stages of infection.
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We believe this is responsible for the increased potency of H-89 compared to Aktspecific inhibitors and is the relevant mechanism for its antibacterial effects. In
conclusion, the isoquinolinesulfonamide H-89 primarily acts on bacterial virulence
pathways rather than host kinases to inhibit infection and represents a new chemical
scaffold for the development of anti-virulence compounds.
Future avenues for H-89 are to synthesize analogs that have limited Akt inhibition
while retaining their antibacterial effects, find its targets in Salmonella, and investigate its
effects on bacterial transcription. Since Akt is part of a major host kinase network, it
would be desirable to find effective analogs that do not affect host cell signaling. Based
on structural and SAR studies, it was shown that the nitrogen in the isoquinoline ring is
essential for kinase binding and inhibition of Akt [143,144]. Analogs with modifications
here should display decreased Akt inhibition while perhaps maintaining antibacterial
activity. The obvious potential pitfall is that H-89’s activity in the bacteria could be due
to kinase inhibition, so modifying the isoquinoline ring could render the compound
inactive. Discovering the bacterial targets of H-89 by non-covalent pull-downs would
shed light on its mechanism and potentially uncover a kinase or kinase network involved
in virulence regulation. My studies have laid the groundwork for using H-89 as a tool
compound for studying bacterial virulence mechanisms in Salmonella. By impairing the
T3SS-dependent stages of infection without affecting growth, H-89 represents a new
chemical scaffold for the development of more potent and selective anti-infectives.
Gaining a better understanding of what H-89 targets, how it affects bacterial
transcription, and the broader effects it has on gene expression could provide an
additional point of intervention for inhibiting bacterial virulence.
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Classically, antimicrobials are small molecules that act as antibiotics to kill
bacteria directly. Due to the increased frequency of antibiotic-resistant strains and with
more knowledge of bacterial pathogenesis, targeting virulence pathways required for
bacterial infection has become an alternative strategy for antimicrobial development.
Two potential benefits are that targeting bacterial pathogenesis as opposed to viability
could make it more difficult for bacteria to develop resistance while preserving the
normal host microbiota. Key virulence mechanisms of many bacterial pathogens like
T3SSs have now been uncovered and are prime targets for chemical intervention. Potent
and specific T3SS inhibitors with validated mechanisms of action are still needed to
establish whether this conserved virulence pathway is indeed a druggable target and
viable approach towards disarming clinically relevant bacterial pathogens. Many of the
virulence factors are essential for causing human diseases but are dispensable for the
growth of pathogens, complicating efforts towards identifying the targets of virulence
inhibitors. It remains to be determined whether the use of anti-virulence compounds
would exert less selective pressure on bacterial pathogens to develop drug resistance as
well as preserve beneficial microbiota in vivo; however, given the current state of
antibacterials, the potential benefits are worth the effort. It is possible that inhibitors of
bacterial virulence could slow the spread of infection and be used in conjunction with
traditional antibiotics [145]. A focused effort on inhibitors of bacterial virulence could
address these major challenges in antibacterial drug discovery and help combat microbial
infections that impact human health.
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CHAPTER 5 – Materials and Methods

Compounds
Most commercially available compounds were purchased from Sigma Aldrich, Fisher
Scientific, Alfa Aesar, or Fluka. All final compounds were stored in 20 mM stock
solutions in DMSO. Reactions were monitored by thin layer chromatography (TLC).
Products were purified by flash column chromatography (FCC). Nuclear magnetic
resonance (NMR) spectra were recorded on either a 400 or 600 MHz Bruker
spectrometer. Chemical shifts are reported in ppm from tetramethylsilane. Coupling
constants are reported as J values in Hertz (Hz). Mass spectra were obtained on a
MALDI-TOF spectrometer or by LC-MS, performed by The Rockefeller University
Proteomics Resource Center. Akti1/2 and MK2206 were gifts from N. Rosen (Memorial
Sloan-Kettering Cancer Center).

5.1 Synthesis of T3SS inhibitor INP-0007 (2.1)
INP-0007 was synthesized according to published procedure [121].

4-nitrobenzohydrazide (2.3)
To 15 mL of EtOH was added p-nitrobenzoate (2 g, 10.2 mmol) and hydrazine
monohydrate (2.5 mL, 41 mmol). The mixture was refluxed at 80 ˚C overnight. The
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precipitate was collected and washed with water to yield 2.3 as a yellowish solid (1.5 g,
80%).
1

H NMR (600 MHz, CDCl3): δ = 4.18 (s, 2H), 7.40 (s, 1H), 7.94 (d, 2H, J = 8.7 Hz), 8.34

(d, 2H, J = 8.7 Hz).

N'-(3,5-dibromo-2-hydroxybenzylidene)-4-nitrobenzohydrazide (INP-0007) (2.1)
To a 1:2 mixutre of EtOH and water (2 mL) was added 2.3 (50 mg, 0.28 mmol). In 2 mL
of EtOH was dissolved 3,5-dibromosalicylaldehyde (85 mg, 0.30 mmol). This mixture
was added to 2.3 and stirred at room temperature until the reaction was complete. The
product was filtered and washed with water, EtOH, and ether before recrystallization in
either to give INP-0007 as a yellow solid (100 mg, 82%).
1

H NMR (600 MHz, DMSO-d6): δ = 7.86 (s, 2H), 8.19 (d, 2H, J = 8.6 Hz), 8.40 (d, 2H, J

= 8.6 Hz), 8.57 (s, 1H). MALDI-TOF calcd for C14H10Br2N3O4 [M+H]+ 441.90, found
441.92.

5.2 Synthesis of photocrosslinking-alkynyl-INP (PC-alk-INP) (2.2)
The synthetic route up to the final coupling step was performed as previously described
[122].

2-(prop-2-yn-1-yloxy)ethan-1-ol (2.4)
1

H NMR (600 MHz, CDCl3): δ = 2.49 (t, 1H, J = 2.3 Hz), 3.68-3.69 (m, 2H), 3.79-3.80

(m, 2H), 4.24 (d, 2H, J = 2.3 Hz).
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2-(prop-2-yn-1-yloxy)ethyl 4-methylbenzenesulfonate (2.5)
1

H NMR (600 MHz, CDCl3): δ = 2.45 (t, 1H, J = 2.3 Hz), 2.47 (s, 3H), 3.75 (d, 2H, J =

4.7 Hz), 4.14 (d, 2H, J = 2.3 Hz), 4.21 (d, 2H, J = 4.7 Hz), 7.36 (d, 2H J = 8.2 Hz), 7.82
(d, 2H, J = 8.2 Hz).

2,2,2-trifluoro-1-(3-methoxyphenyl)ethan-1-one (2.6)
1

H NMR (600 MHz, CDCl3): δ = 3.90 (s, 3H), 7.28 (m, 1H), 7.48 (t, 1H, J = 8.0 Hz),

7.68 (s, 1H), 7.69 (d, 1H, J = 7.8 Hz).

2,2,2-trifluoro-1-(3-methoxyphenyl)ethan-1-one oxime (2.7)
1

H NMR (600 MHz, CDCl3): δ = 3.85 (s, 3H), 7.04-7.11 (m, 3H), 7.40 (t, 1H, J = 7.5

Hz), 8.85 (s, 1H).

2,2,2-trifluoro-1-(3-methoxyphenyl)ethan-1-one O-tosyl oxime (2.8)
1

H NMR (600 MHz, CDCl3): δ = 2.48 (s, 3H), 3.83 (s, 3H), 6.94-7.07 (m, 3H), 7.34-7.40

(m, 3H), 7.89-7.93 (m, 2H).

3-(3-methoxyphenyl)-3-(trifluoromethyl)diaziridine (2.9)
1

H NMR (600 MHz, CDCl3): δ = 2.25 (d, 1H, J = 8.4 Hz), 2.80 (d, 1H, J = 8.4 Hz), 3.85

(s, 3H), 6.99 (d, 1H, J = 8.3 Hz), 7.17 (s, 1H), 7.22 (d, 1H, J = 7.6 Hz), 7.36 (t, 1H, J =
8.0 Hz).
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3-(3-methoxyphenyl)-3-(trifluoromethyl)-3H-diazirine (2.10)
1

H NMR (600 MHz, CDCl3): δ = 3.83 (s, 3H), 6.71 (s, 1H), 6.79 (d, 1H, J = 7.7 Hz), 6.96

(d, 1H, J = 8.3 Hz), 7.33 (t, 1H, J = 8.0 Hz).

2-methoxy-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzaldehyde (2.11)
1

H NMR (600 MHz, CDCl3): δ = 3.94 (s, 3H), 6.70 (s, 1H), 6.84 (d, 1H, J = 8.2 Hz), 7.83

(d, 1H, J = 8.2 Hz), 10.4 (s, 1H).

2-hydroxy-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzaldehyde (2.12)
1

H NMR (600 MHz, CDCl3): δ = 6.80-6.82 (m, 2H), 7.62 (d, 1H, J = 8.1 Hz), 9.95 (s,

1H), 11.08 (s, 1H).

2-(2-(prop-2-yn-1-yloxy)ethoxy)-4-(3-(trifluoromethyl)-3H-diazirin-3yl)benzaldehyde (2.13)
1

H NMR (600 MHz, CDCl3): δ = 2.49 (t, 1H, J = 2.3 Hz), 3.97-3.99 (m, 2H), 4.26-4.29

(m, 4H), 6.77 (s, 1H), 6.86 (d, 1H, J = 12.3 Hz), 7.86 (d, 1H, J = 12.3 Hz), 10.51 (s, 1H).

2-(2-(prop-2-yn-1-yloxy)ethoxy)-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzoic acid
(2.14)
1

H NMR (600 MHz, CDCl3): δ = 2.52 (t, 1H, J = 2.3 Hz), 4.01 (t, 2H, J = 4.4 Hz), 4.29

(d, 2H, J = 2.3 Hz), 4.43 (t, 2H, J = 4.4 Hz), 6.82 (s, 1H), 6.97 (d, 1H, J = 8.2 Hz), 8.22
(d, 1H, J = 8.2 Hz), 10.6 (br. s, 1H).
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2,4-dibromo-6-(hydrazonomethyl)phenol (2.15)
To a mixture of 3,5-dibromosalicylaldehyde (2 g, 7.15 mmol) cooled to 0˚C in 7.5 mL
EtOH was added hydrazine monohydrate (1.8 mL, 28.6 mmol). The mixture was stirred
for 1.5 hours as it was allowed to warm to room temperature. The solid was filtered,
washed with EtOH, water, and ether and dried to yield crude 2.15 in quantitative yield.
1

H NMR (600 MHz, CDCl3): δ = 5.64 (s, 2H), 7.20 (s, 1H), 7.60 (s, 1H), 7.76 (s, 1H).

N'-(3,5-dibromo-2-hydroxybenzylidene)-2-(2-(prop-2-yn-1-yloxy)ethoxy)-4-(3(trifluoromethyl)-3H-diazirin-3-yl)benzohydrazide (PC-alk-INP) (2.2)
In 1 mL dry DCM was added 2.14 (50 mg, 0.15 mmol), oxalyl chloride (262 µL, 3.0
mmol), and 1 drop of DMF. This solution was stirred at room temperature for 1 hour
before being rotovapped. DCM was added and again rotovapped off. This was repeated 2
more times to remove all excess oxalyl chloride. In 1 mL of DCM was dissolved 2.15
(67.6, 0.23 mmol), and this was added to the acid chloride. To this mixture was slowly
added 6 drops of triethylamine. The reaction was stirred at room temperature overnight
and then washed with 10% HCl and brine before being dried over magnesium sulfate,
filtered, and concentrated. The crude product was purified by FCC in 1:1 ethyl
acetate:DCM to yield PC-alk-INP (20 mg, 22%).
1

H NMR (600 MHz, CDCl3): δ = 3.42 (t, 1H, J = 2.5 Hz), 3.85 (t, 2H, J = 4.2 Hz), 4.25

(d, 2H, J = 2.5 Hz), 4.33 (t, 2H, J = 4.2 Hz), 6.92 (s, 1H), 7.79 (d, 1H, J = 2.4 Hz), 7.83
(s, 1H), 7.84 (s, 1H), 7.86 (d, 1H, J = 2.4 Hz), 8.38 (s, 1H). 13C NMR (100 MHz, DMSOd6): δ = 31.2, 58.1, 78.0, 80.6, 80.8, 110.9, 118.8, 121.3, 124.7, 132.5, 132.7, 133.9,
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134.1, 138.3, 138.4, 147.6, 154.1, 157.0, 161.6. LC-MS calcd for C21H15Br2F3N4O4
[M+H]+ 602.94, found 602.97.

5.3 Synthesis of inactive SAH analog
N'-benzylidene-4-nitrobenzohydrazide (SAH-1) (2.16)
To a solution of 4-nitrobenzoylhydrazide (3) (362 mg, 2 mmol) in 33% ethanol (4 mL)
was added benzaldehyde (206 µL, 2.04 mmol) dissolved in 0.5 mL ethanol. The mixture
was stirred for one hour at room temperature before the yellow precipitate was filtered
and washed with cold water, EtOH, and ether to yield the product as a yellow solid (442
mg, 82%).
1

H NMR (600 MHz, DMSO-d6): δ = 7.49 (m, 3H), 7.76 (d, 2H, J = 6.7 Hz), 8.16 (d, 2H,

J = 8.6 Hz), 8.39 (d, 2H, J = 8.6 Hz), 8.48 (s, 1H). 13C NMR (150 MHz, DMSO-d6): δ =
124.1, 127.7, 129.4, 129.7, 130.8, 134.6, 139.7, 149.4, 149.7, 162.0. MALDI-TOF calcd
for C14H12N3O3 [M+H]+ 270.08, found 270.40.

5.4 Synthesis of alkynyl SAHs
ethyl 4-(prop-2-yn-1-yloxy)benzoate (2.19)
To p-Ethyl-hydroxy benzoate (1.5 g, 9 mmol) was added 50 mL of dry DMF. This
solution was cooled to 0 °C before potassium carbonate (1.9 g, 13.5 mmol) was added.
This mixture was stirred for 30 minutes before propargyl bromide (3.01 mL, 27 mmol)
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was added. The solution was warmed to room temperature and stirred for 3 hours. Once
the reaction was complete, ethyl acetate was added, and the solution was washed with 1
N HCl and brine before being dried over magnesium sulfate and concentrated. The
product was purified by flash column chromatography (FCC) in hexanes:ethyl acetate to
give 2.19 (1.7 g, 95 %) as a yellow oil.
1

H NMR (600 MHz, CDCl3): δ = 1.40 (t, 3H, J = 7.1 Hz), 2.57 (t, 1H, J = 2.4 Hz), 4.37

(q, 2H, J = 7.1 Hz), 4.77 (d, 2H, J = 2.4 Hz), 7.01 (d, 2H, J = 8.8 Hz), 8.04 (d, 2H, J = 8.8
Hz).

4-(prop-2-yn-1-yloxy)benzoic acid (2.20)
2.19 (250 mg, 1.22 mmol) was dissolved in a 1:1 mixture of THF and water (3 mL: 3
mL). To this was added sodium hydroxide (122 mg, 3.05 mmol), and the solution was
heated at 60 °C overnight. Upon completion, the THF was evaporated, ethyl acetate was
added, and the mixture was washed with 10 % HCl. The solution was dried with
magnesium sulfate and concentrated to give 2.20 (210 mg, 97 %) as a white solid.
1

H NMR (600 MHz, CDCl3): δ = 2.57 (t, 1H, J = 2.4 Hz), 4.78 (d, 2H, J = 2.4 Hz), 7.04

(d, 2H, J = 13.3 Hz), 8.08 (d, 2H, J = 13.3 Hz).

tert-butyl 2-(4-(prop-2-yn-1-yloxy)benzoyl)hydrazine-1-carboxylate (2.21)
PyBOP (162 mg, 0.31 mmol), BOC-hydrazine (41 mg, 0.31 mmol), and 2.20 (50 mg,
0.28 mmol) were dissolved in 3 mL of DMF. To this was added DIEA (98 µL, 0.56
mmol), and the reaction was stirred overnight at room temperature. Upon completion,
ethyl acetate was added, and the solution was washed with 10 % HCl, sodium
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bicarbonate, and brine before being dried over magnesium sulfate and concentrated to
give the crude product 2.21, which was carried through to the next step.
1

H NMR (600 MHz, CDCl3): δ = 1.48 (s, 9H), 2.52 (t, 1H, J = 2.3 Hz), 4.72 (d, 2H, J =

2.3 Hz), 6.99 (d, 2H, J = 8.7 Hz), 7.76 (d, 2H, J = 8.7 Hz).

4-(prop-2-yn-1-yloxy)benzohydrazide (2.22)
Crude 2.21 (1g, ~3.4 mmol) was added to 18 mL of dry DCM. This mixture was cooled
to 0 °C and to it was added 8 mL of TFA, at which point the reaction bubbled. As the
solution warmed to room temperature, it turned from yellow to orange. The solvent was
evaporated, and the product was resuspended in ethyl acetate, washed with sodium
bicarbonate, dried over magnesium sulfate, and concentrated. The product was purified
by FCC with hexanes:ethyl acetate to yield 2.22 (430 mg, 79 % over 2 steps).
1

H NMR (600 MHz, CDCl3): δ = 2.52 (t, 1H, J = 2.4 Hz), 4.72 (d, 2H, J = 2.4 Hz), 7.01

(d, 2H, J = 8.8 Hz), 7.71 (d, 2H, J = 8.8 Hz).

The final coupling step for synthesizing INP-0007 was also used to synthesize the
alkynyl SAH analogs. In general, 2.22 (25 mg, 0.13 mmol) was dissolved in a 2 mL
mixture of 33% EtOH in water. The corresponding aldehyde (0.14 mmol) was dissolved
in 1 mL of EtOH and added to the solution containing 2.22. The solution was stirred at
room temperature until compound crashed out of solution. The precipitate was collected
and washed with water, cold EtOH, and ether before being dried and recrystallized from
EtOH (81-92% yield).
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N'-(3,5-dibromo-2-hydroxybenzylidene)-4-(prop-2-yn-1-yloxy)benzohydrazide
(alk-INP) (2.17)
1

H NMR (400 MHz, DMSO-d6): δ = 3.63 (t, 1H, J = 2.3 Hz), 4.91 (d, 2H, J = 2.3 Hz),

7.13 (d, 2H, J = 8.9 Hz), 7.81 (s, 1H), 7.81 (s, 1H), 7.94 (d, 2H, J = 8.9 Hz), 8.51 (s, 1H).
13

C NMR (100 MHz, DMSO-d6): δ = 56.1, 79.1, 79.2, 110.8, 111.6, 115.3, 121.5, 125.4,

130.1, 132.5, 132.7, 136.0, 147.1, 154.1, 160.8, 162.9. LC-MS: calcd for C17H12Br2N2O3
[M+H]+ 450.92, found 451.00.

N'-benzylidene-4-(prop-2-yn-1-yloxy)benzohydrazide (alk-SAH) (2.18)
1

H NMR (400 MHz, DMSO-d6): δ = 3.58 (t, 1H, J = 2.3 Hz), 4.87 (d, 2H, J = 2.3 Hz),

7.07 (d, 2H, J = 8.6 Hz), 7.41 (m, 3H), 7.68 (d, 2H, J = 6.4 Hz), 7.87 (d, 2H, J = 8.6 Hz),
8.41 (s, 1H). 13C NMR (100 MHz, DMSO-d6): δ = 55.9, 78.6, 79.2, 115.2, 125.9, 127.6,
127.9, 129.3, 129.9, 130.1, 131.0, 134.3, 148.9, 160.4, 164.1. LC-MS: calcd for
C17H14N2O2 [M+H]+ 279.11, found 279.17.

N'-(2-hydroxybenzylidene)-4-(prop-2-yn-1-yloxy)benzohydrazide (alk-OH) (2.23)
1

H NMR (400 MHz, DMSO-d6): δ = 3.63 (t, 1H, J = 1.3 Hz), 4.91 (d, 2H, J = 2.3 Hz),

6.93 (m, 2H), 7.12 (d, 2H, J = 8.4 Hz), 7.29 (m, 1H), 7.52 (d, 1H, J = 7.6 Hz), 7.93 (d,
2H, J = 8.4 Hz), 8.62 (s, 1H).

13

C NMR (100 MHz, DMSO-d6): δ = 56.1, 79.1, 79.3,

115.1, 116.8, 119.2, 119.7, 126.0, 129.9, 130.1, 131.7, 148.3, 157.9, 160.5, 162.7. LCMS: calcd for C17H14N2O3 [M+H]+ 295.10, found 295.17.
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N'-(5-bromo-2-hydroxybenzylidene)-4-(prop-2-yn-1-yloxy)benzohydrazide
(alk-5’Br) (2.24)
1

H NMR (400 MHz, DMSO-d6): δ = 3.62 (t, 1H, J = 2.1 Hz), 4.90 (d, 2H, J = 2.1 Hz),

6.89 (d, 1H, J = 8.8 Hz), 7.11 (d, 2H, J = 8.7 Hz), 7.43 (d, 1H, J = 8.8 Hz), 7.78 (s, 1H),
7.93 (d, 2H, J = 8.7 Hz), 8.59 (s, 1H). 13C NMR (100 MHz, DMSO-d6): δ = 56.1, 79.1,
79.3, 110.9, 115.2, 119.1, 121.8, 125.9, 130.1, 130.9, 131.1, 133.9, 145.8, 156.9, 160.6,
162.8. LC-MS: calcd for C17H13BrN2O3 [M+H]+ 373.01, found 373.08.

N'-(4-bromo-2-hydroxybenzylidene)-4-(prop-2-yn-1-yloxy)benzohydrazide
(alk-4’Br) (2.25)
1

H NMR (400 MHz, DMSO-d6): δ = 3.62 (t, 1H, J = 2.3 Hz), 4.90 (d, 2H, J = 2.3 Hz),

7.10-7.14 (m, 4H), 7.52 (d, 1H, J = 8.3 Hz), 7.92 (d, 2H, J = 8.4 Hz), 8.60 (s, 1H). 13C
NMR (100 MHz, DMSO-d6): δ = 56.1, 79.1, 79.2, 79.3, 115.2, 119.0, 119.5, 119.6,
122.9, 124.2, 126.0, 129.9, 130.1, 130.9, 131.0 146.6, 158.5, 160.5, 162.7. LC-MS: calcd
for C17H13BrN2O3 [M+H]+ 373.01, found 373.08.

N'-(3-bromo-2-hydroxybenzylidene)-4-(prop-2-yn-1-yloxy)benzohydrazide
(alk-3’Br) (2.26)
1

H NMR (400 MHz, DMSO-d6): δ = 3.58 (t, 1H, J = 1.3 Hz), 4.87 (d, 2H, J = 1.3 Hz),

6.87 (m, 1H), 7.11 (d, 2H, J = 8.3 Hz), 7.46 (d, 1H, J = 7.6 Hz), 7.58 (d, 2H, J = 7.9 Hz),
7.91 (d, 2H, J = 8.3 Hz), 8.52 (s, 1H). 13C NMR (100 MHz, DMSO-d6): δ = 56.1, 79.1,
79.2, 79.2, 110.4, 115.3, 119.9, 121.0, 125.5, 130.0, 130.2, 130.8, 134.6, 134.8, 148.6,
154.7, 160.7, 162.8. LC-MS: calcd for C17H13BrN2O3 [M+H]+ 373.01, found 373.08.
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N'-(3,5-dibromo-2-methoxybenzylidene)-4-(prop-2-yn-1-yloxy)benzohydrazide (alkOMe) (2.27)
1

H NMR (400 MHz, DMSO-d6): δ = 3.63 (t, 1H, J = 2.4 Hz), 3.82 (s, 3H), 4.91 (d, 2H, J

= 2.4 Hz), 7.12 (d, 2H, J = 8.8 Hz), 7.92-7.97 (m, 3H), 8.00 (s, 1H), 8.62 (s, 1H).

13

C

NMR (100 MHz, DMSO-d6): δ = 56.1, 79.2, 79.3, 115.1, 117.8, 119.2, 126.2, 130.0,
130.2, 131.8, 136.5, 137.3, 140.8, 155.3, 160.6, 163.0. LC-MS: calcd for C18H14Br2N2O3
[M+H]+ 464.94, found 465.00.

N'-(3,5-dibromo-2-hydroxybenzyl)-4-(prop-2-yn-1-yloxy)benzohydrazide (red-alkINP) (2.28)
To a solution of alk-INP (17) (50 mg, 0.111 mmol) in 3 mL of MeOH:THF (1:2 mL) was
added sodium cyanoborohydride (21 mg, 0.332 mmol). The solution turned yellow. To
this mixture was added 10% HCl in MeOH (2 mL). A whitish precipitate crashed out of
solution. The precipitate was collected and dissolved in EtOAc, washed with water and
sodium bicarbonate, dried over magnesium sulfate, filtered and concentrated to yield 2.28
(35 mg, 70%).
1

H NMR (400 MHz, DMSO-d6): δ = 3.60 (t, 1H, J = 2.2 Hz), 4.02 (s, 2H), 4.87 (d, 2H, J

= 2.2 Hz), 7.05 (d, 2H, J = 8.8 Hz), 7.39 (s, 1H), 7.63 (s, 1H), 7.80 (d, 2H, J = 8.8 Hz).
13

C NMR (100 MHz, DMSO-d6): δ = 52.5, 56.0, 79.1, 79.3, 110.5, 111.7, 115.0, 115.1,

125.9, 128.1, 129.4, 129.6, 131.7, 131.8, 133.5, 133.8, 153.6, 160.2, 166.3. LC-MS: calcd
for C17H14Br2N2O3 [M+H]+ 452.94, found 452.92.
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5.5 Bacterial strains and eukaryotic cell lines for SAH experiments
Wild-type S. typhimurium strain IR715, which is a nalidixic acid-resistant strain of
14028, was used for all experiments unless otherwise noted. The SPI-1 T3SS-deficient
mutant (ΔinvA) was taken from the Salmonella deletion library [36]. The SopE2-CPG2HA strain was used as previously described [50]. HeLa cells were grown in DMEM
supplemented with 10% FBS at 37˚C in a 5% CO2 incubator.

5.6 Isolation of secreted SPI-1 effector proteins
Overnight cultures of S. typhimurium grown in Luria-Bertani broth (LB) in a 37˚C shaker
were diluted 1:30 and grown for four hours in the presence of compound or DMSO.
Bacteria were pelleted by centrifugation at 15,000 g for 10 minutes. The supernatant was
removed and spun down again to remove any remaining bacteria. The secreted proteins in
1 mL of the remaining supernatant were precipitated overnight at 4˚C with 10%
trichloroacetic acid (TCA). The proteins were pelleted by centrifugation at 20,000 g for
30 minutes, and the supernatant was discarded. The pellet was washed with acetone to
remove remaining TCA and pelleted again. The acetone washes were done a total of
three times before the pellet was resuspended in 35 µL 4% SDS buffer, 12.5 µL loading
buffer, and 2.5 µL BME. The samples were vortexed, heated at 95˚C, and run on an SDSPAGE gel for 1 hour at 200 volts. The precipitated secreted proteins were visualized by
staining the gel with Coomassie blue.
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5.7 Characterization of secreted effector proteins
Once the secreted proteins were separated by SDS-PAGE, protein bands were visualized
by Coomassie blue staining and identified by in-gel trypsinization followed by LCMS/MS analysis. Briefly, each band in the gel was cut into small slices, which were
subsequently washed for 15 minutes in 250 mM ammonium bicarbonate (ABC), twice in
1:1 ABC to acetonitrile (ACN), and once in ACN before drying. Once dry, 2 µg of
trypsin in 30 µL ABC was added to each slice before overnight incubation at 37°C. The
liquid was collected, and the gel slices were washed in 1:1 ABC:ACN + 0.1%
trifluoroacetic acid (TFA) twice, collecting the liquid after each wash [112]. The
combined supernatants were dried under vacuum before being resuspended in 0.1% TFA
in water for LC-MS/MS analysis (performed by The Rockefeller University Proteomics
Resource Center). Sequest and X!Tandem data was imported into Scaffold for Peptide
Prophet filtering. Peptides with ≥95% likelihood of correct assignment were accepted.
Proteins matched with 2 or more tryptic peptides were accepted; for those proteins, nontryptic peptides were also accepted.

5.8 Bacterial lysis
Overnight cultures were diluted 1:30 and grown for four hours in the presence of
compound or DMSO. They were pelleted and washed with PBS before lysis. A lysis
buffer cocktail was made by adding 100 µL of 0.1% SDS buffer (0.1% SDS, 150 mM
NaCl, 50 mM TEA, pH 7.4), 4 µL PMSF (250 mM in ethanol), 2 µL 250x protease
inhibitor (Roche), and 0.1 µL benzonase per sample. The cell pellets were resuspended in
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100 µL of the lysis buffer and sonicated 2x30 seconds before being put on ice for 10
minutes and sonicated again. Cell debris was removed by spinning at 1,000 g for 5
minutes and collecting the supernatant. Protein concentration was determined using a
BCA assay.

5.9 Click chemistry protocol and in-gel fluorescence analysis
A click chemistry cocktail was made by mixing 1 µL of copper sulfate (50 mM), 1 µL of
TCEP-HCl (50 mM), 2.5 µL TBTA (2mM), and 0.5 µL azido-Rhodamine (10mM) per
sample [113]. To 50 µg of lysate in 45 µL of 4% SDS buffer was added 5 µL of the click
chemistry cocktail was added. The samples were vortexed, and the reaction was
performed for one hour at room temperature in the dark before being precipitated with
200 µL MeOH, 75 µL chloroform, and 150 µL water. The solution was vortexed then
centrifuged for 2 minutes at 20,000 g. The top layer was removed, and again 200 µL of
MeOH was added before the pellet was spun down. This MeOH wash was repeated and
the samples were left to dry. Once dry, 35 µL of 4% SDS buffer, 12.5 µL loading buffer,
and 2.5 µL BME were added to each sample. The tubes were heated at 95°C for 5
minutes and separated by SDS-PAGE. The proteins were visualized by scanning the gel
with an Amersham Biosciences Typhoon 9400 imager (excitation 532 nm, 580 nm filter,
30 nm band-pass).
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5.10 Transcriptional profiling of S. typhimurium
Performed by Angelica Ferguson. Overnight cultures were inoculated at 1:30 dilution and
compound was added to a final concentration of 20 µM. Cultures were grown for four
hours and then harvested by centrifugation. RNA was extracted using the RNeasy Protect
Bacteria Mini Kit (Qiagen) according to the manufacturer’s protocol for bacterial cells.
Equivalent masses of RNA from each sample (1-2.5 µg) were reverse transcribed using
Affinity Script RT enzyme (Stratagene) and oligo dT (Roche). cDNA was diluted 50-fold
with water, and PCR reactions were performed in triplicate with specific primers using
SYBR green (Roche) and Platinum Taq polymerase (Roche). Reactions were run on a
384-well plate using the Roche Lightcycler. Normalization was performed using rrsH and
rpoD (rRNA and housekeeping gene, respectively) mRNA levels. Analysis was
performed using the comparative Ct method and fold inductions of compound-treated
samples were calculated over DMSO-treated values.

5.11 Secretion and expression of SopE2-CPG2-HA
Performed as previously described [50]. SopE2-CPG2-HA-expressing bacteria were
grown in the presence of compound or DMSO for four hours. The bacteria were spun
down to separate them from the supernatant. The pellet was washed once with PBS and
lysed in 1% Brij buffer (1% Brij-97, 150 mM NaCl, 50 mM TEA, pH 7.4) by sonicating
twice for 30 s each, separated by 10 min on ice. To 20 µL of the supernatant and 5 µg of
the lysate in 20 µL Brij buffer was added 80 µL Glu-CyFur buffer (10 µM Glu-CyFur, 50
mM Tris, 0.1 mM ZnCl2, 0.1% Brij-97, pH 7.4). CyFur fluorescence was monitored on a
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SpectraMax M2 multi-detection reader (Molecular Devices) for one hour at 610 nm with
excitation at 563 nm as a readout of SopE2-CPG-HA secretion and expression,
respectively.

5.12 Proteomic identification of modified proteins
5.12.1 Bacterial lysis
This protocol is described in [112]. Overnight cultures of bacteria were diluted 1:30 in
LB and grown in the presence of 50 µM compound or DMSO for four hours before being
washed with PBS and flash-frozen. Typically 10-20 mL cultures were used to obtain
larger amounts of protein. The bacteria were lysed by resuspending the pellet in 1 mL of
0.1% SDS buffer (0.1% SDS, 150 mM NaCl, 50 mM TEA, pH 7.4), 40 µL PMSF (250
mM in ethanol), 20 µL 250x protease inhibitor (Roche), 1 µL benzonase, and 10 µL of
lysozyme (from 10 mg/mL solution in water) per sample and put on ice for 10 minutes.
The solutions were sonicated 2 x 30 seconds and iced again for 10 minutes, at which
point 500 µL of 12% SDS buffer was added. The solution was sonicated again for 2 x 30
seconds. If the solution is not clear, more SDS buffer can be added and the sonication
repeated. Once the solution is mostly clear, the cell debris can be removed by
centrifuging at 1,000 g for 5 minutes and collecting the supernatant. Protein concentrated
was estimated by BCA assay.
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5.12.2 Click chemistry reaction with azido-biotin
Equal amounts of protein (~5 mg) per sample were brought up to 7 mL in 1% Brij buffer
with 2 mL of 10% SDS buffer being added to that. A click chemistry cocktail can be
mixed before being added to each sample. The cocktail contained 100 µL of azido-biotin
(10 mM) (Fig 1.x), 200 µL copper sulfate (50 mM), 200 µL of TCEP-HCl (50 mM), and
500 µL TBTA (2mM) per sample. To each sample was added 1 mL of the click
chemistry cocktail. The samples were vortexed and placed in the dark at room
temperature for 1.5 hours. In order to precipitate the protein, the samples were split into
two 5 mL solutions in 50 mL Falcon tubes. To each sample was added 20 mL cold
MeOH, 7.5 mL chloroform, and 15 mL water. The samples were vortexed and spun at
5,250 g for 30 minutes. Similar to the click reaction with azido-Rhodamine, the top layer
was removed, 20 mL of MeOH was added, and the samples were spun at 5,250 g for 30
minutes again. This MeOH wash was repeated one more time before the samples were
allowed to dry for several hours. Once dry, the pellets were resuspended in 1 mL of 4%
SDS buffer containing 20 µL of 0.5 M EDTA solution, and protein concentration was
estimated by BCA assay.

5.12.3 Binding the protein to streptavidin beads
Streptavidin beads (100 µL for 5 mg of protein) were washed in PBS, spun down at 4,000
g for 2 minutes, and resuspended in an equal volume of 1% Brij buffer. The beads were
pipetted with chopped pipet tips. To 5 mg of protein in 3 mL of Brij buffer in a 15 mL
Falcon tube was added 100 µL of the pre-washed streptavidin beads. The mixture was
rocked at room temperature for 1 hour. The beads were then extensively washed to
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remove any non-specifically-bound proteins, spinning at 3,000 g for 2.5 minutes after
each wash. They were first washed twice with 10 mL 0.2% SDS in PBS, followed by 3
washes with 10 mL of PBS, then 2 washes of 10 mL of ABC (250 mM in water). The
beads were then incubated in 500 µL urea (8 M in ABC), 25 µL TCEP (200 mM in
water), and 25 µL iodoacetamide (390 mM in water) for 1 hour at room temperature to
reduce and cap the cysteines. The beads were washed 2 more times with ABC,
transferred to a dolphin tube, and spun down.

5.12.4 Eluting the protein from the beads and concentrating the sample
To each sample was added 250 µL of an elution buffer consisting of 50 mL ABC (250
mM), 50 mg SDS, and 218 mg sodium dithionite (Na2S2O4). The solution was gently
mixed and incubated at room temperature for one hour. The beads were then spun down
at 5,000 g for 1 minute, and the eluent was collected. The elution step was repeated with
200 µL of elution buffer, with the beads being incubated for 30 minutes. The beads were
again spun down, and the eluents were combined. To concentrate the eluent, centricons
(10,000 kDa MW cutoff; Millipore) were first washed with water and spun at 14,000 g
for 15 minutes. The eluent was then added to the centricons and spun at 14,000 g for 15
minutes. The centricons were inverted and placed into a new tube and spun at 1,000 g for
3 minutes to collect the concentrated sample. They were rinsed with 50 µL of 1% SDS
containing 75 mM BME. This solution was collected by spinning the centricon upside
down at 1,000 g for 3 minutes. This rinsing step was repeated before the concentrated
sample was dried on a speedvac.
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5.12.5 Separating the sample by SDS-PAGE and preparing it for mass spec analysis
The dried powder was resuspended in 25 µL LDS buffer with 5% BME (per 100 µL of
buffer needed: 25 µL 4x LDS buffer (Invitrogen), 5 µL BME, 70 µL water). The samples
were vortexed and heated on a 95oC heating block before being loaded on an SDS-PAGE
gel with blank lanes between each sample. The blank lanes contained 1x LDS buffer with
14% SDS and 5 % BME. The gel was run for 1 hour at 200 volts before being stained
with Coomassie blue. Lanes were cut into slices and prepared as in 5.7. Identified
proteins had 2 unique peptides with 95% confidence. High-confidence hits had 10x the
spectral counts as the background.

5.13 S. typhimurium invasion of HeLa cells
HeLa cells were grown in 12-well plates containing DMEM with 10% FBS. Bacteria
grown in the presence of compound or DMSO were added at an MOI of 10 in
DMEM/10% FBS containing compound or DMSO before being centrifuged at room
temperature for 5 min at 1000 x g. The plates were placed in a 37˚C incubator for a 30minute invasion period. Cells were then washed three times with room temperature PBS
containing 100 ug/mL gentamicin and then incubated with DMEM/10% FBS containing
100 ug/mL gentamicin at 37oC for an additional 30 minutes to kill all extracellular
bacteria. Cells were then washed an additional three times with PBS containing 100
ug/mL gentamicin to remove any remaining extracellular bacteria. Cells were trypsinized
then fixed with 3.7% paraformaldehyde in PBS for 10 minutes. They were then
permeabilized with 0.2% saponin in PBS for 10 min and blocked with 2% FBS in PBS
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for 10 min. All antibody stainings and washes were performed with ice-cold 0.2%
saponin in PBS. Cells were stained with anti-Salmonella rabbit serum (Biodesign
International) for one hour at room temperature before being washed three times. Goat
anti-rabbit secondary antibody conjugated to AlexaFluor 488 (Invitrogen) was added for
30 minutes before cells were washed 3 times. Flow cytometry was performed using a
Becton Dickinson LSRII machine and FlowJo software was used for analysis.

5.14 Bacterial strains, plasmids, and eukaryotic cell lines for H-89 experiments
Wild-type S. typhimurium strain IR715, which is a nalidixic acid-resistant strain of
14028, was used for all experiments unless otherwise noted. Overnight cultures grown in
Luria-Bertani broth (LB) at 37˚C were diluted 1:30 and grown for four hours in the
presence of compound or DMSO. For construction of the SseJ-HA strain (provided by
Markus Grammel), initially a pWSK29_HA plasmid was generated by annealing two
primers

(TCGAGTTATGCATAATCAGGAACATCATAAGGATAG

and

AATTCTATCCTTATGATGTTCCTGATTATGCATAAC), digesting them with EcoRI
and XhoI, and ligating them into pWSK29, which was also digested with EcoRI and
XhoI.

SseJ

was

amplified

from

S.

typhimurium

(GAATTCTTCAGTGGAATAATGATGAGCTATAAAAC

(IR715)

by

PCR
and

TCTAGAGATAGCAGTCAGATAATATGTACCAGGC). The resulting PCR product
was digested with EcoRI and XbaI and ligated into pWSK29-HA plasmid, also digested
with EcoRI and XbaI. The SopE2-CPG2-HA strain was used as before (5.11). HeLa cells
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and RAW264.7 macrophages were grown in DMEM supplemented with 10% FBS at
37˚C in a 5% CO2 incubator.

5.15 Bacterial replication in macrophages
Macrophages were grown in 12-well plates containing DMEM with 10% FBS. They
were infected with Salmonella typhimurium for one hour in a 37˚C incubator at a
multiplicity of infection (MOI) of 5 before being washed three times with 100 µg/mL
gentamicin in PBS. DMEM containing 10% FBS and 20 µM of compound or DMSO and
10 µg/mL gentamicin was added to the cells and incubated for 16 hours before CFU
plating. From each sample were plated 3 dilutions (10-5-10-7) in triplicate for CFU counts.

5.16 Western blotting for Akt during macrophage infection
For Akt blots, macrophages in 6-well plates were infected in the same manner as for CFU
plating, but instead they were harvested 8 hours pi, lysed in 30 mM Tris/HCl pH 7.5, 150
mM NaCl, 1% Triton X-100, Halt Phosphatase Inhibitor Cocktail (Thermo Scientific),
and EDTA-free protease inhibitor cocktail (Roche). Protein concentration was estimated
by BCA assay, and equal amounts of protein were separated on an SDS-PAGE gel before
being transferred to a nitrocellulose membrane. The membrane was probed with
antibodies (Cell Signaling Technology) for total Akt levels and phospho-Akt (Ser473).
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5.17 Imaging macrophages and secreted SseJ-HA during infection
For imaging experiments, macrophages grown on cover slips in 12-well plates were
infected for one hour at an MOI of 1. At this point, they were washed three times with
100 µg/mL gentamicin in PBS before being resuspended in DMEM containing 10% FBS
and 10 µg/mL gentamicin. At 5 hours pi, compound was added, and cells were incubated
for two more hours before being fixed and stained. All antibody stainings and washes
were performed with ice-cold 0.2% saponin in PBS. Cells were stained with antiSalmonella rabbit serum (Biodesign International) for one hour followed by goat antirabbit secondary antibody conjugated to AlexaFluor 488 (Invitrogen) for 30 minutes.
Then cells were stained with mouse anti-HA (Sigma) antibody for one hour followed by
goat anti-mouse secondary antibody conjugated to Rhodamine Red (Invitrogen) for 30
minutes. DNA was stained with TO-PRO-3 for five minutes before imaging. Cells were
washed three times between each staining. All microscopy was performed on a Zeiss
LSM 510 laser scanning confocal microscope.
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APPENDIX
1

H and 13C NMR spectra
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